 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 1 of 36 
 WIRELESS TRANSCUTANE OUS ELECTRICAL NERVE STIMULATION (TENS) F OR 
CHEMOTHERA PY-INDUCED PERIPHERAL  NEUROPATHY: A PHASE  II CLINICAL TRIAL  
 
URCC19085  
NCT # 04367480  
 
URCC NCORP Research Base:  
Saunders Research Building 
265 Crittenden Blvd, Room 2.235  
CU 420658 
Rochester, NY 14642  
  
Phone:  585- 275-1364  
Fax:  585- 461-5601  
website:  http://urcc -ncorp.org/  
Study  Chair:  
 Jennifer S. Gewandter , PhD, MPH  
601 Elmwood Ave, Box 604 
Rochester, NY,  14642  
 
Study Co-Chairs:  
  Karen Mustian , PhD, MPH  
Gary Morrow, PhD, MS  
URCC NCORP Research Base  
 
NCORP Co -Chair s: 
 James N. Atkins , MD  
Southeast Clinical Oncology Research 
Consortium  
 Brian Burnette, MD  
Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium  
 
Medical Monitor:  
 Nimish Mohile, MD, MS  
University of Rochester Medical Center  
 
Biostatistician s: 
 Eva Culakova, PhD, MS  
Charles Heckler, PhD, MS  
URCC NCORP Research Base  
 
Participating Institutions:    • This study is open to  all NCORP sites that are 
affiliated with URCC.  
 
IDE:  Not applicable, TENS devi ce is currently marketed for relief of chronic pain and considered minimal 
risk by the FDA and thus only requires IRB approval (https://www.fda.gov/medical -devices/device- advice-
investigational -device- exemption- ide/ide -approval -process#non_sig_risk ) 
 
Device(s) /supplier :  TENS devices will be supplied by Neurometrix  at no cost.  
 Distributed by :   URCC NCORP Research Base  
 
Document History  Version Date  
Initial  10-18-2019  
Revised  12-16-2019  
Amendment 1  1-24-2020  
Amendment 2  3-11-2020  
Amendment 3  6-25-2021  
  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 2 of 36 
 Study Collaborators     Kathleen Sluka , PhD  
University of Iowa 
Iowa City, IA 52242  
  
 
 
 
Protocol Contact Information  
 
Protocol Coordinator : Alexandra O’Connell  
585-275-1067  
URCC_19085@URMC.Rochester.edu  
 
Adverse Event  Reporting : Sarah Strause  
585-275-1398  
URCC_ 19085@urmc.rochester.edu  
 
Regulatory Contact:  Scarlett Montanaro  
585-275-1361  
URCC_Regulatory @urmc.rochester.edu  
 
Website/Registration Contact:  Sebastien Estaque  
585-275-2044  
URCC_Techsupport @urmc.rochester.edu  
 
General Questions  URCC_NCORP@urmc.rochester.edu  
 
 
  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx25/2021  Page 3 of 36 
 SCHEMA  
 
 
  

 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 4 of 36 
 TABLE OF CONTENTS  
 
1. INTRODUCTION AND BACKGROUND ............................................................... 6 
1.1 Rationale  ......................................................................................................................................................... 6 
1.2 Literature Revie w ........................................................................................................................................... 6 
1.3 Pilot trial of wireless TENS device for CIPN from our group.  ....................................................................... 7 
1.4 Feasibility  ....................................................................................................................................................... 8 
2. AIMS/OBJECTIVES  .............................................................................................. 8 
2.1  Primary Aim.  .................................................................................................................................................. 8 
2.2  Secondary Aim 1.  ........................................................................................................................................... 8 
2.3  Secondary Aim 2.  ........................................................................................................................................... 8 
2.4  Explora tory Aim 1  .......................................................................................................................................... 8 
2.5  Exploratory Aim 2  .......................................................................................................................................... 8 
3. CHARACTERISTICS OF STUDY POPULATION ................................................. 9 
3.1 Inclusion Criteria  ............................................................................................................................................ 9 
3.2 Exclusion Criteria  ........................................................................................................................................... 9 
3.3  Source of Study P articipants  ......................................................................................................................... 10 
3.4 Patient Identification, Eligibility Screening, and Recruitment  ...................................................................... 10 
4. REGISTRATION  .................................................................................................  10 
4.1 CTEP Registration Procedures ...................................................................................................................... 10 
4.2 CTSU Registration Procedures  ..................................................................................................................... 11 
4.3 Requirements for Submitting Regulatory Documents to the URCC Research Base  .................................... 12 
4.4 Coordinator requirements  ............................................................................................................................. 12 
4.5 Enrolling Participants .................................................................................................................................... 13 
5. RESEARCH PROTOCOL/STUDY PROCEDURES  ............................................ 14 
5.1 Protocol Equipment Shipping Distribution  ................................................................................................... 14 
5.2  Study Device  ................................................................................................................................................. 14 
5.3  Schedule of study procedures  ....................................................................................................................... 15 
5.4 Study Measures  ............................................................................................................................................. 18 
5.5 Potential Risks  .............................................................................................................................................. 21 
5.6 Emergency Study Device Disclosure  ............................................................................................................ 21 
5.7 Costs to the Participant .................................................................................................................................  22 
5.8 Payment for Participation  ............................................................................................................................. 22 
5.9 Contraindications  .......................................................................................................................................... 22 
5.10 Concomitant Medications  ............................................................................................................................. 22 
5.11 Adherence  ..................................................................................................................................................... 22 
6.  Study Device Distribution  .................................................................................... 23 
6.1 Availability  ................................................................................................................................................... 23 
6.2 Distribution  ................................................................................................................................................... 23 
6.3  Device Accountability  .................................................................................................................................. 23 
6.4 Packaging and Labeling  ................................................................................................................................ 23 
6.5 Storage  .......................................................................................................................................................... 23 
7.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION .......................... 23 
7.1 Primary Endpoint  .......................................................................................................................................... 24 
7.2 Off-Devi ce Criteria  ....................................................................................................................................... 24 
7.3 Off-Study Criteria  ......................................................................................................................................... 24 
8.0 REPORTING ADVERSE EVENTS  ..................................................................... 24 
8.1 Definitions  .................................................................................................................................................... 24 
8.2 Serious Adverse Event (SAE).  ...................................................................................................................... 24 
8.3 Reporting  ...................................................................................................................................................... 25 
8.4 Responsibilities for Expedited Reporting  ..................................................................................................... 26 
9. STUDY MONITORING  ....................................................................................... 27 
9.1 Data Management Summary  ......................................................................................................................... 27 
9.2 Schedule of Data Collection  ......................................................................................................................... 27 
9.3 Data and Safety Monitoring Plan  .................................................................................................................. 28 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 5 of 36 
 9.4 Record Retention  .......................................................................................................................................... 29 
10. STATISTICAL CONSIDERATIONS  .................................................................... 29 
10.1  Quality Control.  ............................................................................................................................................ 29 
10.2  Anal ysis set and Missing Data.  ..................................................................................................................... 29 
10.3  Sample Size Estimation.  ............................................................................................................................... 30 
10.4  Primary Analysis.  .......................................................................................................................................... 30 
10.5  Secondary Analyses  ...................................................................................................................................... 30 
10.6  Exploratory Analyses.  ................................................................................................................................... 30 
10.7  Sensitivity analyses.  ...................................................................................................................................... 31 
10.8  Feasibility analyses.  ...................................................................................................................................... 31 
10.9  Evaluation of Toxicity/Adverse Events  ........................................................................................................ 31 
10.10  Interim Analysis  ............................................................................................................................................ 31 
10.11  Anci llary Studies  ........................................................................................................................................... 31 
11. ETHICAL AND REGULATORY CONSIDERATIONS  ......................................... 31 
11.1 Form FDA 1572 ............................................................................................................................................ 31 
11.2 Other Req uired Documents (IND studies only)  ............................................................................................ 32 
11.3 Institutional Review Board Approval ........................................................................................................... 32 
11.4 Regulatory Approval Process of the Informed Consent Document  .............................................................. 32 
11.5 Submission of Regulatory Documents  .......................................................................................................... 32 
11.6 Other  ............................................................................................................................................................. 32 
12. REFERENCES  ................................................................................................... 32 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 6 of 36 
 1. INTRODUCTION AND BACKGROUND  
 
1.1 Rationale  
 
CIPN occurs in approximately 60% of patients who receive neurotoxic chemotherapeutic agents (e.g., 
platinums, taxanes, and vinca alkaloids) and becomes chronic (i.e., lasts at least 3 months after termination 
of chemotherapy) in approximately 50% of those individuals. [1] Neurotoxic agents are used to treat many 
common cancers including breast, gastrointestinal, lung, ovarian, and myeloma, which together were estimated to make up ~40% of new U.S. cancer cases in 2018. [2] CIPN presents as a variable combination 
of neuropathic symptoms, commonly including burning and shooting pain, tingling, cramping, and 
numbness. Data from our group and that of others suggest that chronic CIPN leads to functional limitations such as impaired balance, [3, 4] increased falls, [5-8] limitations in activities of daily living (e.g., s hopping), [5] 
and interference with walking. [9, 10] Multiple studies demonstrate that CIPN is associated with decreased 
quality of life in cancer survivors. [11] No gold -standard treatments are available for CIPN. While duloxetine 
modestly improved chronic painful CIPN in one randomized clinical trial (RCT), [12] this drug contributes to 
the adverse effects of polypharmacy. No treatments have been shown to mitigate the functional limitations 
that are associated with CIPN such as impaired balance or walking. In fact, our recent systematic review 
of RCTs evaluating pharmacologic treatments for CIPN found that only two trials reported performance-
based function measures, [13] suggesting a gap in research methods for current CIPN RCTs. B ased on its 
high prevalence, severity, effects on quality of life, and lack of available treatments, CIPN is among the 
highest priority research areas for the NCI Community Research Program (NCORP). [14, 15] 
 
Numerous possible pathophysiol ogical mechanisms for CIPN have been proposed. Given the expertise of 
our research group and the analgesic mechanisms of transcutaneous electrical stimulation (TENS) (see 
next section), we will focus on the potential role of the alteration of two opposing pathways that control 
sensation in the brain: (1) central excitatory pathways (i.e., central excitability) and (2) central descending 
inhibitory pathways (i.e. , descending inhibition). Central excitatory pathways in the spinal cord amplify 
signals to the brain from the ascending sensory neurons (i.e., nociceptive neurons). In contrast, central inhibitory signals from the brainstem and spinal cord inhibit signals  from nociceptive neurons .[16-18] Unlike 
central exci tability, the function of descending inhibition can be tested in humans (via a conditioned pain 
modulation (CPM) test [19]) and will be investigated in the proposed study. In animal models of CIPN, 
dorsal horn neurons that transmit noxious sensory signals show enhanced responsiveness to noxious 
stimuli, suggesting enhanced central excitability. [20-23] Expression of glutamate transporters in the dorsal 
horns of animals with CIPN is decreased, [20, 24, 25] which would result in enhanced concentrations of the 
excitatory neurotransmitter glutamate. Simultaneously, endogenous opioids, which inhibit nociceptive 
transmission, are decreased in animal models of CIPN. [26] Finally, a study of 27 participant s showed that 
reduced descending inhibition (measured via CPM test) was associated with more severe CIPN 
symptoms. [27] Together these data suggest that CIPN may be associated with enhanced central 
excitability and reduced descending inhibition and that our proposed intervention, TENS, reduces central excitability and increases descending inhibition (Figure 1). [28-32] 
 1.2 Literature Review  
 
TENS is a promising therapy for CIPN.  TENS is the application of electrical stimulation through the skin. 
It is a safe, non -pharmacologic, non- addictive, and inexpensive therapy used clinically for pain control. The 
waveform, frequency, and maximum current of the electrical stimulation vary among devices, but the 
proposed mechanisms of action are similar. [28] Evidence suggests that TENS reduces central excitability 
and activates descending inhibition, both of which have been implicated in CIPN in animal studies and one 
small human study. In animal models, TENS reduces the enhanced central excitability of nociceptive 
neurons induced by inflammation and nerve injury [33] and decreases the release of the excitatory 
neurotransmitter glutamate in the dorsal horn of the spinal cord. [32] TENS also produces analgesia in 
animal models by activating descending inhibition in the brainstem and spinal cord through activation of 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx25/2021  Page 7 of 36 
 endogenous opioid receptors. [30, 31, 34] Consistently, human studies show opioid receptor activation by 
TENS during pain inhibition[ 35] and show that TENS restores descending inhibition in individuals with 
fibromyalgia during a  single TENS session. [29]  
 
TENS is efficacious for chronic pain and promising for non-painful neuropathy symptoms in other 
conditions.  The efficacy of TENS for pain is supported by its widespread clinical use as well as positive 
results from RCTs in various chronic pain conditions, including peripheral neuropathic pain. [29, 36-46] 
However, these RCTs are generally small and not blinded. RCTs in cluding  patients with diabetic peripheral 
neuropathy showed improvements in discomfort and in a composite neuropathy score that includes ratings of pain, numbness, and prickling sensations, [36, 37] suggesting that TENS could also reduce non -painful 
neuropathy symptoms. Furthermore, dysmenorrhea and writer’s cramp, for which RCT data supports the 
efficacy of TENS  [41, 43, 45] involve cramping pain, and our preliminary results suggest that CIPN -related 
cramping may  be particularly responsive to TENS (Table 1).  
 
Preliminary, single -arm studies of TENS treatments for CIPN  from the published literature.  A single -
arm study showed that TENS delivered at acupuncture points by a licensed technician reduced CIPN -
related numbness. [47] Another single- arm study showed that scrambler therapy, a type of TENS treatment 
that delivers 16 different waveforms of stimulation, reduced CIPN symptoms. [48] While these results are 
promising, rigorous evaluation of TENS for CIPN requires randomization and blinding. Furthermore, interventions like scrambler therapy involve expensive equipment and travel to a clinic. Our proposed 
research will evaluate the effects of TENS delivered with a wireless, home- based, patient -managed, 
economical device that has greater potential for clinical dissemination than interventions that require clinician application.   
 1.3 Pilot trial of wireless TENS device for CIPN from our group.  
We performed a single -site, single -arm pilot study of a wireless TENS device for chronic CIPN. [49] After a 
baseline screening week to record daily symptoms, the participants  were asked either to wear  the device 
for one hour in the morning or one hour in the evening or to wear the device for up to 12 h/day  on the 
continuous setting that alternates between 1h treatment and 1h rest periods. Patient Reported Outcome (PRO ) measures were completed at baseline and after 6 weeks, at which time qualitative interviews were 
performed.  
TENS effects on CIPN:  Our pilot study  (n=26 enrolled, 22 completed and included in Table 1 analyses)  
showed a significant 10% improvement in CIPN (via CIPN20
61, p=0.006). Individual lower limb symptoms 
(0–10 numeric rating scales (NRSs)) improved considerably (Table 1). Qualitative interviews supported 
these symptom improvements and the acceptability of the device (Table 2).  
 
Safety:  Only one participant had a notable skin reaction, which is the most documented risk of TENS, and 
this participant  wore the device for longer than  12 hours / day against our advice because of his perceived 
large benefit of the therapy. Three participants  developed new abnormal sensations. For two of those 

 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 8 of 36 
 participants  the abnormal sensations subsided after they stopped using the device. One subject preferred 
to continue using the device regardless of the abnormal sensations because of the perceived benefit to 
her CIPN symptoms.  
 
1.4 Feasibility  
 
A key advantage of conducting this study within the NCORP network is the demonstrated track record of 
the group in recruiting participants who report moderate CIPN at least 3 months after completion of 
chemotherapy (based on a previous successful phase III  clinical trial) . In that trial , 342 cancer survivors 
were recruited in 19 months (i.e., 18 patients/month) at the top 5 accruing NCORP sites of the URCC 
Research Base.[50] The proposed study was rated the #1 priority by NCORP site investigators  of all the 
concepts that were presented at both the 2017 and 2018 University of Rochester Cancer Center (URCC) NCORP Research Base annual meetings.  Eight NCORP sites ha ve officially committed to recruiting for 
the study.  In terms of this specific study design and intervention, data from our pilot study support feasibility. 
Seventy -two percent (26/36) of eligible patients received the device. This high enrollment rate, in  
combination with the recruitment rate in our previous NCORP RCT, suggests that  recruitment of at least 
13 participants  per month (i.e., the recruitment goal  for the proposed study) using 8  NCO RP sites will be 
feasible.  22 of 26 (85%) participants completed the 6 weeks of treatment and the PRO assessments . 
Eighteen  (82%) of the participants who completed the first 6 weeks of the study  chose to continue wearing 
the device after the 6 -week primary endpoint. Seventy -seven percent  of the participants who completed 
the primary 6 -week phase of the study  reported that they preferred to wear the device on the continuous 
setting (mean ~ 8 hours /day) rather than for 2 individual 1 hour sessions. These data suggest that wearing 
the device on the continuous setting for 5 hours /day (i.e., 3  hours of TENS stimulation in the active group) 
will be acceptable to most participants.  Furthermore, this should provide at least 75% of the stimulation 
that most participants in the pilot trial rec eived to achieve similar treatment effects.  All participants will be 
given and allowed to keep an active device for free upon completion of the study , further encouraging 
recruitment  and retention . 
 
2. AIMS/ OBJECTIVES  
 
2.1  Primary Aim.  Obtain efficacy estimates of daily TENS on CIPN (European Organisation for 
Research and Treatment of Cancer -CIPN20  (EORTC -CIPN20 )) to inform the design of a phase III 
confirmatory trial.  
 
2.2  Secondary Aim 1.  Obtain efficacy estimates of TENS on individual CIPN symptoms (i.e., 
hot/burning pain, sharp/ shooting pain, tingling, numbness, cramping (measured daily via 0 – 10 
Numeric Rating Scale ( NRS )).  
 
2.3  Secondary Aim 2.  Evaluate the feasibility  of conducting, within the URCC NCORP network, a 
multisite, modified double- blind RCT of TENS for CIPN with physiologic assessments of 
descending inhibition (i.e., conditioned pain modulation (CPM) test)  by assessing the proportions 
of (a) screened patients who enroll, (b) randomized participants who adh ere to the treatment and 
complete the primary assessment, and (c) randomized participants who complete the CPM test.  
 
2.4  Exploratory  Aim 1 Investigate the potential effects of TE NS on balance, physical function,  
descending inhibition, lower limb sensation, and anxiety and depression.  
 
2.5  Exploratory Aim 2 Establish data to support the construct validity of the Treatment -Induced 
Neuropathy Assessment Scale ( TNAS) and CIPN symptom inventory  daily diary  by comparison to 
the EORTC -CIPN20, which is the most commonly used measure of CIPN.  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 9 of 36 
 3. CHARACTERISTICS OF S TUDY POPULATION  
 
3.1 Inclusion Criteria  
 
Participants  must :  
1. Have completed treatment with a platinum agent, tax ane, vinca alkaloid, or bortezomib at least 3 
months prior  to registration . See Appendix 1 for a list of drugs included in these drug classes.  
2. Have a clinical diagnosis of CIPN from their physician or physician designee  based on the following 
criteria: bilateral  (i.e., present on both sides of the body) , abnormal sensory symptoms in their feet 
or legs (e.g., hot/burning pain, sharp/ shooting pain, numbness, tingling, cramping) . 
3. Report at least 1 non- painful symptom associated with CIPN in their lower limbs  (e.g., tingling, 
burning that isn’t reported as painful , numbness ) 
4. Report at least 2 of the following symptoms in their lower limbs  (at their worst)  as at least 4 out of 
10 on a 0 –  10 NRS : hot/burning pain, sharp/ shooting pai n, numbness, tingling, cramping  at Visit 1 
(i.e., Week -1).  Use the CIPN Symptom Inventory –  Week Recall form (questions 1 -5 ONLY ) to 
assess these symptoms at screening.  
5. Be willing and able not to start any new analgesic medications or change the dosages of any current 
analgesic medications (except acetaminophen (Tylenol)  or NSAIDs  (i.e., ibupro fen (Advil, Motrin), 
Naproxen (Aleve) ) for the duration of the study . 
6. Be able to read English (i.e., is not illiterate, can speak English, and is not blind) . 
7. Be at least  18 years of age.  
8. Have access to a smart phone or device with an Apple or Android operating system  that can be 
used to access the TENS device’s App and ability to connect to the internet  on a daily basis during 
the trial . 
 3.2 Exclusion Criteria  
 
Participants must not:  
1. Have pre- existin g neuropathy of any cause documented in their medical record prior to the start of 
chemotherapy or respond “yes” to the question “Did you have frequent numbness, tingling, 
sharp/shooting pain, hot/burning pain, or cramping in your feet before you started your 
chemotherapy ?” 
2. Have unilateral CIPN symptoms  (i.e., symptoms occur on predominantly only one side of the body) . 
3. Be currently using a TENS device for any other reason.  
4. Be currently taking, or have taken in the past 3 months,  medications known to cause neuropathy 
in a significant portion of patients (list of excluded drugs provided in Appendix  2). 
5. Have an acute and symptomatic lower extremity DVT (treated DVT with resolution of symptoms is 
acceptable for enrollment) . 
6. Lower extremity edem a that is 2+ or greater (i.e., slight indentation that takes less than 15 seconds 
to rebound) . 
7. Have started a new prescription pain medication or altered dosages of a prescription pain 
medication within the last 2 weeks . 
8. Have lower extremity wounds or ulcers . 
9. Have a cardiac pace maker  or defibrillator . 
10. Have epilepsy.  
11. Have a leg that is too small or too  large for the TENS device to fit securely.  
12. Have missing lower limbs or amputations.  
13. Have impaired decision making capacity  (i.e., requires a legally authorized representative or health 
care proxy) . 
14. Be pregnant or planning to get pregnant before expected completion of the study . 
15. Participate in another clinical trial for CIPN.  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 10 of 36 
 3.3  Source of Study Participants  
 
a. Partic ipants will be recruited at 8 NCORP s within the URCC Research Base network  
 
b. Eligible participants will be aged 18 or older  because the TENS device is not approved for 
children 
 
Table 3. Planned Enrollment Table 
Racial Categories Not Hispanic or 
Latina:  
 
Female  Not Hispanic or 
Latino:  
 
Male  Hispanic or 
Latina:  
 
Female  Hispanic or 
Latino:  
 
Male   
Total  
American Indian/Alaska Native  0 0 0 0 0 
Asian  6 2 0 0 8 
Native Hawaiian or Other Pacific 
Islander  1 0 0 0 1 
Black or African American  10 6 2 0 18 
White  83 34 2 1 120 
More Than One Race  1 1 1 0 3 
Total  101 43 5 1 150 
 
3.4 Patient Identification, Eligibility Screening,  and Recruitment  
 Patient Identification.   Potential participants will be identified in a HIPAA -compliant manner by research 
staff through review of scheduled outpatient appointments or chart review  with clinicians (e.g., medical 
oncologists  or nurse practitioners ). Informational flyers will also be used to facilitate recruitment. In order 
to document reasons for ineligibility or refusal, a  screening log  will be completed for patients who are 
approached, but do not consent. This form will not collect any identifiable information or demographics unrelated to reasons for ineligibility. This information is critical to inform design of  a future phase III trial.    
 Consent Process .  Patients who meet all eligibility criteria  will be provided with a copy of the CIRB -
approved informed consent document to review. The investigator/investigator’s designee will explain all 
aspects of the study in lay language and answer all questions regarding the study. Key elements of the informed consent procedure that will be explained to all participants are: 1) the fact that the study is 
research ; 2) the prospect of potential skin irritation and new, likely reversible, abnormal sensations in their 
lower limbs ; 3) the lack of guarantee of benefit from participation; 4) the confidentiality of the participant’s 
responses;  5) the voluntary nature of the study;  and 6) the freedom to withdraw from the study or to refuse 
to answer specific questions or perform specific tests at any time. If the patient  decides to participate in 
the study, he or she  will be asked to sign and da te the informed consent document. All consented 
participants will be provided with a copy of the signed consent form.  
 
4. REGISTRATION  
 
4.1 CTEP Registration Procedures 
 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require all individuals contributing to NCI -sponsored trials to register and to renew their registration annually. To 
register, all individuals must obtain a Cancer Therapy Evaluation Program (CTEP) Identity and Access 
Management (IAM) account at https:// ctepcore.nci.nih.gov/iam
. In addition, persons with a registration ty pe 
of Investigator (IVR), Non- Physician Investigator (NPIVR), or Associate Plus (AP) (i.e., clinical site staff 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 11 of 36 
 requiring write access to OPEN, Rave, or acting as a primary site contact) must complete their annual 
registration using CTEP’s web- based Regist ration and Credential Repository (RCR) at 
https://ctepcore.nci.nih.gov/rcr.    
 
RCR utilizes 5  person registration types.  
• IVR — MD, DO, or international equivalent;  
• NPIVR — advanced practice providers (e.g., NP or PA) or graduate level researchers (e.g., PhD);  
• AP — clinical site staff (e.g., RN or CRA) with data entry access to CTSU applications (e.g., Roster 
Update Management System ( RUMS), OPEN, Rave,);  
• Associate (A) — other clinical site staff involved in the conduct of NCI -sponsored trials; and  
• Associa te Basic (AB) —  individuals (e.g., pharmaceutical company employees) with limited access 
to NCI -supported systems.  
 
Table 4. RCR requires the following registration documents:  
Documentation Required  IVR NPIVR  AP A AB 
FDA Form 1572  ✔ ✔    
Financial Disclosure Form  ✔ ✔ ✔   
NCI Biosketch (education, training, employment, license, and 
certification)  ✔ ✔ ✔   
GCP training  ✔ ✔ ✔   
Agent Shipment Form (if applicable)  ✔     
CV (optional)  ✔ ✔ ✔   
 
An active CTEP -IAM user account and appropriate RCR registration is required to access all CTEP and 
Cancer Trials Support Unit (CTSU) websites and applications. In addition, IVRs and NPIVRs must list all clinical practice sites and Institutional Review Boards (IRBs) covering their practice sites on the FDA Form 
1572 in RCR to allow the following:  
• Addition to a site roster;  
• Assign the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN;  
• Act as the site -protocol Principal Investigator (PI) on the IRB approval; and  
• Assign the Clinical Invest igator (CI) role on the Delegation of Tasks Log (DTL).  
 In addition, all investigators act ing as the Site- Protocol PI, consenting/treating/drug shipment  receiver , or 
as the CI on the DTL must be rostered at the enrolling site with a participating organization (i.e., Alliance).  
Additional information is located on the CTEP website at 
https://ctep.cancer.gov/investigatorResources/default.htm
. For questions, please contac t the RCR Help 
Desk by email at RCRHelpDesk@nih.gov . 
 
4.2 CTSU Registration Procedures 
 
This study is supported by the NCI Cancer Trials Support Unit (CTSU).  
 4.2.1  IRB Approval  
 Because this is an NCI CIRB -approved study and all NCORPs  are participating in CIRB, the NCORPs  are 
not required to submit separate IRB approval documentation to the CTSU Regulatory Office for initial, continuing or amendment review. IRB approval informati on is received from the CIRB and applied to the 
Regulatory Support System (RSS) in an automated process.  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 12 of 36 
 Sites participating with the NCI CIRB must submit the Study Specific Worksheet for Local Context (SSW) 
to the CIRB using IRBManager  to indicate their intent to open the study locally. The NCI CIRB’s approval 
of the SSW is automatically communicated to the CTSU Regulatory Office, but sites are required to contact 
the CTSU Regulatory Office at CTSURegPref@ctsu.coccg.org  to establish site preferences for applying 
NCI CIRB approvals across their Signatory Network. Site preferences can be set at the network or protocol level. Questions about establishing site preferences can be addressed to the CTSU Regulatory Office by 
emailing the email address above or calling 1 -888-651-CTSU (2878).  
 
In addition, the Site- Protocol Principal Investigator (PI) (i.e. the investigator on the IRB/REB approval) must 
meet the following criteria to complete proces sing of the IRB/REB approval record:  
• Holds an Active CTEP status;  
• Rostered at the site on the IRB/REB approval and on at least one participating roster;  
• If using NCI CIRB, rostered on the NCI CIRB Signatory record;  
• Includes the IRB number of the IRB providing approval in the Form FDA 1572 in the RCR profile; 
and 
• Holds the appropriate CTEP registration type for the protocol.  
 
Additional Requirements 
 
Additional requirements to obtain an approved site registration status include:  
• An active Federal Wide Assur ance (FWA) number;  
• An active roster affiliation with the Lead Protocol Organization (LPO) or a Participating Organization 
(PO); and  
• Compliance with all protocol -specific requirements (PSRs).  
 
 
4.3 Requirements for Submitting Regulatory Documents to the URCC Research Base  
 Submit your CIRB -approved Annual Signatory Institution Worksheet, Annual Principal Investigator 
Worksheet and your Informed Consent Documents to URCC_Regulatory @urmc.rochester.edu for the 
URCC Research Base study records.  
 
4.4 Coordinator requirements  
 
Up to 10 NCORPs will be allowed to participate in the study; participating NCORPs will be determined by 
the PI, Dr. Gewandter, based on their  interest and demonstrated ability to open the study at their sites. If 
at all possible, e ach site should have 2 coordinators available to participate in the study.  One will be blinded 
to the treatment assignment  (i.e., “ assessor ”) and will perform all of the assessments and the other will 
know the treatment assignment  (i.e., “unblinded coordi nator”)  and will introduce the study to the participant, 
teach them how to use the TENS device, and answer any phone calls regarding trouble shooting of the 
device.  If it is not possible for the site to have 2 coordinators dedicated to the study, a single coordinator 
can perform all of the study activities as long as they complete both trainings. The fact that there is one 
coordinator should be documented so that the potential effect of the lack of blinding on the outcomes can 
be assessed. If only one coordinator is available at a site, all places in the remainder of the protocol that 
refer to the “blinded” or “unblinded” coordinator should be interpreted as the “coordinator” for that site.  
Sites who only have one coordinator  available must obtain pe rmission from the study PI to use a single 
coordinator for both roles. Permission can be requested by emailing the study mailbox at URCC_19085@urmc.rochester.edu.  
 4.4.1 Training for assessor  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 13 of 36 
 The assessor  will be trained to support reliable implementation of the conditio ned pain modulation (CPM) 
test, short physical perform ance battery –  balance subscale , and lower limb sensation test  using a 
combination of webinars , pre-recorded videos,  in person meetings, or written materials . Each coordinator 
will be re quired to perform each evaluation on  a mock participant with the Study Chair or Study Chair’s 
designee  watching (in person or via video conferencing or via previously recorded videos  submitted to the 
Research Base ) in order to ensure correct implementation. The CPM test training may  also involve 
evaluation of the consistency at which the coordinator increases the pressure using data from the device. 
These  process es may be repeated at the Study Chair’s  request depending on performance . Once the 
Study Chair is satisfied with the coordinator’s implementation, the coordinator will be certified to act as the 
blinded coordinator for the study.  Ideally, the same assessor will perform the baseline and endpoint 
assessments f or an individual participant.  
 
4.4.2 Training for the unbli nded coordinator  
 
The unblinded coordinator will be trained using a combination of webinars, pre -recorded videos, in person 
meetings, or written materials to use a standardized script to support consistent introduction of the TENS 
device to the participant and to implement  calibration of the TENS device. They will also be trained on how 
to create a Quell health App account using a de- identified Study Email  for eac h participant. Each 
coordinator will be required to perform these processes on a mock participant  with the Study Chair or Study 
Chair’s designee  watching ( in person or via video conferencing or via previously recorded videos submitted 
to the Research Base ) in order to ensure correct implementation. This process may be repeated at the 
Study Chair’s  request depending on performance. Once the Study Chair is satisfied with the coordinator’s 
implementation, the coordinator will be certified to act as the unblinded coordinator for the study.  
 
Participating  coordinators/staff will be trained to screen, consent, and enroll patients prior to beginning the 
study. These activities can be performed by staff members other than the assessor and unblinded 
coordinator.  
 
4.5 Enroll ing Participant s 
 
The Oncology Patient Enrollment Network (OPEN) is a web- based registration system available on a 
24/7 basis. OPEN is integrated with CTSU regulatory and roster data and with the Lead Protocol 
Organization (LPOs) registration/random ization systems or Theradex Interactive Web Response System 
(IWRS) for retrieval of patient registration/randomization assignment. OPEN will populate the patient 
enrollment data in NCI’s clinical data management system, Medidata Rave.  
Requirements for OPEN access:   
• A valid CTEP -IAM account ; 
• To perform enrollments or request slot reservations:  Be on a LPO roster, ETCTN Corresponding 
roster, or PO roster with the role of Registrar. Registrars must hold a minimum of an AP 
registration ty pe; 
• If a Delegation of Tasks Log (DTL) is required for the study, the registrar(s) must hold the OPEN 
Registrar task on the DTL for the site; and  
• Have an approved site registration for a protocol prior to patient enrollment.  
 
To assign an Investigator (IVR ) or Non -Physician Investigator (NPIVR) as the treating, crediting, 
consenting, drug shipment (IVR only), or receiving investigator for a patient transfer in OPEN, the IVR or 
NPIVR must list the IRB number used on the site’s IRB approval on their Form FDA 1572 in RCR. If a 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 14 of 36 
 DTL is required for the study, the IVR or NPIVR must be assigned the appropriate OPEN -related tasks 
on the DTL.  
Prior to accessing OPEN, site staff should verify the following:  
• Patient has met all eligibility criteria within the protocol stated timeframes; and  
• All patients have signed an appropriate consent form and HIPAA authorization form (if 
applicable).  
Note:   The OPEN  system will provide the site with a printable confirmation of registration and treatment 
information.  Please print this confirmation for your records.   
Access OPEN at https://open.ctsu.org or from the OPEN link on the CTSU members’ website. Further 
instructional information is in the OPEN section of the CTSU website at https://www.cts u.org  or 
https://open.ctsu.org . For any additional questions, contact the CTSU Help Desk at 1- 888-823-5923 or 
ctsucontact@westat.com . 
 
The following additional information will be requested:  
a. Name of the unblinded coordinator  
b. Name of assessor  
 
An email confirmation of registration will be forwarded.  
 
5. RESEARCH PROTOCOL/ST UDY PROCEDURES  
 
5.1 Protocol Equipment Shipping Distribution  
 
Upon receipt of the NCORP’s IRB approval for this study, and upon request  from the NCORP , the 
Research Base will ship a study start -up package. This request should be made through  the study mailbox 
(i.e., URCC_19085@urmc.rochester.edu ). The start -up package will  contain 1  conditioned pain modulation 
(CPM) test kit , 1 monofilament set , and 4 alternative size elastic bands for use with the TENS device. The 
CPM test kit will include a pressure algometer  and test materials.  
 
Each NCORP site will designate a research staff member to be responsible for receiving the  study start -
up package . The staff member will verify that the shipment contains all supplies  and that the supplies are 
in good condition. They will verify and record the identification numbers for accuracy. The Investigational 
Device Accountability Record  (DARF) will be used to track supplies arriving from the URCC NCORP 
Research Base and CPM kits  and monofilament sets  shipped back to the URCC NC ORP Research Base 
at the end of the study.  
 5.2  Study Device  
 TENS is listed as nonsignificant risk in the 2006 FDA ’s “Significant Risk and Nonsig nificant Risk Medical 
Devices” G uidance. [51] The device that will be used in the study has been cleared by the FDA under 
K152954. It is currently legally marketed in the U .S. for the relief of chronic pain.  Therefore, no IDE is 
necessary for this study. The device is a wireless transcutaneous electr ic nerve stimulation ( TENS ) device 
that emits a high frequency (i.e., 60– 100 Hz) stimulation (waveform is biphasic with alternating leading 
phase) . The device is controlled by an App that is available on Apple and Android devices. The device 
alternates bet ween a 1  hour treatment period and 1 hour rest period on the continuous setting. Participants 
will be asked to wear the device for 5 hours per day on the continuous setting every day for 6 weeks. They 
will be asked to alternate the leg they wear it on each day in order to minimize potential skin reactions.  
 
The active device emits electrical stimulation for the entire 1 hour treatment period, resulting in 3 hours of 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 15 of 36 
 total stimulation in 5 hours of wear. The dosing of the active arm was increased from the m inimum dosage 
in our pilot study to maximize the amount of TENS stimulation  since longer duration of stimulation has 
been linked to larger effect .[52] Additionally, t he company that manufactures the device encour ages 
individuals to use the device for at least 3 sessions per day based on the usage data and pain relief results 
that they have collected from their App data. This prescription is likely acceptable to participant s based on 
participant feedback from our pilot  (see Feasibility section 1.4 ). The unblinded research coordinator will 
walk the participants through the device’s calibration process , which sets the intensity at 1.8 times the 
participant’s sensation threshold. Participants in the active group will then be instructed to increase the 
intensity of the stimulat ion to the point that it is slightly below the intensity  that is uncomfortable.  The device 
will then remember the personalized intensity setting established at this initial visit  for subsequent 
treatment sessions.  However, participants will be allowed to c ontrol the intensity of the stimulation using 
the App throughout the study.  The strategy of asking participants in the active group to increase the 
intensity until the stimulation is as strong as possible without being uncomfortable is based on previous 
research indicating  that the strongest tolerable stimulation is the most effective. [28]  
 
The identical looking placebo device emits 2 minutes of stimulation with a 30 second ramp down of intensity  
followed 57.5 minutes  of no stimulation in the treatment session, which results in 7.5  minutes of stimulation 
in 5 hours. The placebo dose is designed to minimize TENS exposure but enhance blinding.  We have 
shown that a brief stimulation provided by a placebo device blinds par ticipants better than a device with 
no stimulation. [53] Participants in the placebo group will not be prompted to increase the sti mulation until 
it is strong but comfortable because the stimulation will not continue sufficiently long after the calibration 
process to do so.  
 
5.3  Schedule of study procedures 
 
5.3.1 Screening  / Consent  Visit (Day - 7; -2/+3 days)  (approximately 1 hour ) 
 
Eligible p articipant s who provide informed consent will be registered and given the daily diary of CIPN 
symptoms and rescue pain medication consumption,  and trained on how to complete it  at home during the 
Baseline Week (i.e., between the Screening and Baseline Visits) . They will complete the CPM test and 
lower limb sensation test. Chemotherapy t reatment notes will be collected for all consented participants.  
 
5.3.2 Reminder phone call  (Day -2: -1/+1 business day ) 
 
A research staff member will call the participant to remind them of the date of their Baseline Visit and to 
bring the completed forms with them.  
 
5.3.3  Baseline Visit  (Day 0)  (approximately 1 hour ) 
 All participants will be randomized according to procedures in S ection 5.3 .4 after they arrive for the 
baseline visit.  They  will complete the PROs , balance tests,  CPM  test, and lower limb sensation test . At 
this time the participants will be given the TENS device (see Section 5.2 for details of the device) and 
sufficient electrodes for 6 weeks of the study. They will be trained  on how to use the TENS device.  Using 
a standardized script to  limit variation in  expectations , the unblinded coordinator will lead all participants 
through the  calibration process to identify their ideal intensity setting. The unblinded coordinator will train 
the participants on how to use the device at home.  The unblinded coordinator will also download the 
Quell Health Account App to the participant’s smartphone or other device (e.g., iP ad) and create a Quell 
Health Account using a de- identified Study Email for the participant. The Study Email will be 
NCORP19085xxx[xxx= participant ID number] @mail.com.  
The coordinator  will then train the participant to use the App to start the TENS therapy and to open the 
App at least 1x per day when their mobile device or tablet  is connected to the internet so that their de-
identified usage data will be uploaded to the cloud. Participant s will be asked not to modify settings in the 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 16 of 36 
 App other than the intensity  on the main screen for the 6 weeks of the study. The usage  data (i.e., number 
of sessions per day, time the device is on the skin, and the intensity of the last session that occurred before 
connecting the device to the internet)  will be downloaded from the Quell Health Account by the TENS 
device manufacturer and provided to the research team  for use in promoting adherence (see Section 5.3.7  
Phone calls ). The participants will be given a daily di ary to com plete during Weeks 4 (i.e., day 21 – 28) 
and 6 (i.e., day 35 –  42) in which they will record their daily symptoms and rescue pain medication 
consumption.  
 
5.3.4  Randomization/Stratification  
 
A computer -generated randomization schedule will be used to randomize participants  1:1 to the two 
intervention conditions stratified by study site in random block  sizes of 2 and 4 . The schedule will be 
prepared by a URCC NCORP Research Base biostatistician. The coordinator will use the Randomization 
form in REDCap  to ob tain the randomization assignment at the Baseline Visit.  
 The two study arms are as follows:  
a. Active TENS Device  
b. Placebo TENS Device  
 
A total enrollment of 150 participants is planned, with up to 75 participant s randomized to each intervention 
group.  Note, that participants who discontinue prior to randomization (i.e., between the screening and 
baseline visits) will not be replaced. It should take approximately 12 months to accrue all participants.  
 
Table 5. Schedule of Events*  
Week  Screening  
And 
Registration  Randomization  Distribution 
of Study 
Device  Self-
Report 
Measures  Functional 
Exam 
Measures  Coordinator 
open 
participant 
Quell App  Adverse 
Event 
Monitoring  
Screening 
(Visit 1)  X       
Baseline  
(Visit 2)   X X X X   
1       X 
2        
3       X 
4        
5       X 
6 (Visit 3)     X X X X 
*Daily diary completed between screening and baseline visit and during Weeks 4  (i.e., day 21 –  28) and 
6 (i.e., day 35 –  42). Participants will be called 4 weeks after the end of the study (i.e., Week 10) and 
asked if they are using the commercial device).  
 5.3.5   Blinding  
 
The active and placebo devices will look identical, light up in the same manner, and have identical 
packaging. We have shown that a brief stimulation provided by a placebo device blind s participants better 
than a device with no stimulation. [53] Participants and the research coordinators who implement  the 
assessments (i.e., the blinded coordinato r or assessor ) will be blinded to the treatment assignment. An 
unblinded coordinator will teach the participants to use the device, following an almost identical script for 
both treatment groups. The script will convey that some people feel the TENS sensat ion more than others 
and sometimes the sensations fade over the duration of a treatment session. There will be 2 additions to 
the script for the active group. First,  a section asking the participants to increase the stimulation after the 
initial device cal ibration until it first feels uncomfortable and then turn the intensity  down one click  (i.e., 5% 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 17 of 36 
 of the stimulation strength) in order  to obtain the optimal “strong but c omfortable” stimulation intensity . 
Note, that this will not be done in the placebo group because the stimulation will not continue sufficiently 
long after the calibration process for this to happen.  Second, a sentence suggesting that the active group 
may increase the intensity manually dur ing the treatment sessions if desired. The unblinded coordinator 
will be available to troubleshoot difficulties with the device throughout the study. This modified double- blind 
design will maintain a blinded outcomes assessor by having an unblinded coordinator who can respond to 
participant s’ questions that could reveal the participants’ group assignments. The participants will be 
instructed not to discuss any aspect of the TENS device with the blinded coordinator  or other participants 
in the study . The coordinators will be instructed not to discuss the details of the placebo device with the 
participants. The unblinded coordinator and the assessor will be instructed not to discuss details of study 
participants  with each other. Blinding success will be assessed (see measures).  
 
5.3.6  At home procedures (Days 21-28; 35 -42) 
 
Participants  will complete a daily diary including the CIPN Symptom I nventory and consumed rescue 
analgesic medication (i.e., acetaminophen (Tylenol) or NSAIDs). They will be asked to complete it before 
bedtime when they are not wearing the device during weeks 4  and 6 .  
 
5.3.7  Study Phone Calls  (Days 7, 21, 35 ; (up to +  3 working days)  
 
At each phone call, the unblinded coordinator  will assess adverse events (AEs) (see complete descript ion 
of AE assessment in Section 8), troubleshoot adherence problems, remind participants to complete their 
Daily Diaries (Days 21 and 35 only) , and answer participants’ questions. It is important that phone calls 
are made only by the unblinded coordinator because participants’ questions or concerns could lead to unblinding of the assessor. To facilitate targeted adherence optimization, participant s’ device usage data  
from the Device App will be monitored during the study and provided to the unblinded coordinator . Each 
participant’s device usage data will be downloaded from their de- identified Quell health  account  by the 
staff at Neurometrix and  provided to the Research Base  prior to the Day 7,  21, and 35  phone calls . The 
Quell health account data will be identified by the unique Study E mail (i.e., 
NCORP 19085xxx[ xxx=participant ID number] @mail.com ) used  to establish the account and will not 
ident ify the participants . The Research Base staff will summarize the data in a report f or each participant  
prior to the Day 7, 21, and 35  phone calls. These reports will be provided to the unblinded NCORP site 
coordinator at least 1 day prior to the day of the scheduled phone call. If a participant is not using the 
device as prescribed, the unblinded coordinator will enquire about any problems that the participant is 
having with the device and help to troubleshoot those problems. They will also encour age adherence to 
the treatment protocol.  During the D ay 35 phone call, the unblinded coordinator will also remind the 
participant of the date and time of the 3
rd study visit (i.e., W eek 6 visit).  
 
5.3.8  End of Study  Visit  (Day 42; +/ - 5 days)  (approximately 1 hour  and 15 minutes ) 
 
All participants will complete the patient -reported outcom e measures, balance tests, conditioned pain 
modulation test , and lower limb sensation test . The coordinator will also review the list of medications that 
the participant reported using for CIPN at the beginning  of the study and ask the participant if they changed 
dosages of any of the medications. Any changes will be recorded in the C hanges in c oncomitant analgesic 
medications form.  The coordinator will ask the  participant for their device and open the Quell App to ensure 
final data transfer to the cloud. The data will then be downloaded by the device manufacturer and sent to 
the Research Base.  If the participant does not come to the Week 6 visit, the coordinat or will call them up 
to 3 times to try to reschedule the visit. The rescheduled visit can occur up to 1 month after the date of the 
6-week visit. If the participant refuses rescheduling, the coordinator will ask them why they are 
discontinuing the study. I f the participant agrees to come back in, they will be encouraged to keep using 
the device until the rescheduled visit date.   
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 18 of 36 
 5.3.9. Follow -up phone call (Day 70 +/ -5 days)  
 
Coordinators will call participants and ask them whether they are using the commercial device.  
 
5.4 Study Measures  
 
The effects of the TENS intervention on CIPN symptoms and related functioning will be measured using 
patient -reported outcome (PRO) measures and  functional assessments  (see complete list below) . 
 
Demographic and Clinical Information.   Demographic information will be obtained from all participants 
through the use of a standardi zed self -report questionnaire (i.e., On Study  form) . Variables to be assessed 
include age, height, weight, race, ethnicity, education, current work status, and occupation. Participants 
will also be asked to list all medications and treatments previously or currently used to treat their CIPN. 
Participants will also be asked if they have diabetes , edema,  and commonly overlapping  pain condit ions,  
whether they drink alcohol, and if s o, how much they consume weekly . Finally, they will be asked to rank 
how distressing typical CIPN symptoms are for them. The following clinical variables will be assessed via 
medical record review for all participants  and recorded on the Clinical record information f orm: 
“neurotoxic cancer therapy  (i.e., platinum, taxane, vinca alkaloid, bortezomib) (class, agent, date of last 
dose),  type of non- study related chemotherapies, cancer diagnosis for which participant received the 
neurotoxic cancer therapy , history of chemotherapy other than study related chemotherapy (Yes/No and 
date of last dose), history of radiotherapy (past/current/No and date of last treatment), history of hormonal therapy (past/current/No and dat e of last dose)” , history of diabetes (Y/N), history of alcoholism (Y/N),  
history of common overlapping pain conditions , current edema,  and current medications that could affect 
CIPN.
 
 
Patient Reported Outcome M easures  
 
CIPN will be evaluated in 3 ways in this learning phase study . The purpose of measuring CIPN in 3 ways 
is to identify the best measure to use as a primary outcome measure in a confirmatory trial. The European Organisation for Research and Treatment of Cancer -CIPN20 ( EORTC -CIPN20) is one of the most 
commonly used measures of CIPN  (i.e., legacy measure) , however, it includes items that are focused only 
on the upper extremities that may not change in response to TENS  administered on the lower limb as well 
as items that may not be highly specific to CIPN.  The Treatment -Induced Neuropathy Assessment Scale  
(TNAS) is a relatively newer measure that has less data  supporting its psychometric properties , but has 
well established content validity and does not include questions that are focused only on the upper limbs. 
Finally, the CIPN symptom inventory includes similar items to the 2 validated measures, but focuses solely on the lower limbs  and sensory symptoms that we hypothesize will be modified by TENS . In addition , by 
administering it in a daily diary and averaging the ratings over 1 week at baseline and endpoint, as is the 
current practice in most chronic pain trials, variability in CIPN symptoms may be minimized,  therefore 
increasing the assay sensitivity (i.e.,  ability of the measure to detect a true treatment effect) of the outcome 
measure. By including all 3 measures we will contribute t o the validation of the newer measures and 
hopefully identify the measure that has the best assay sensitivity for  measuring C IPN in the lower limbs. 
See below for further description of each measure.  
 
(1) European Organisation for Research and Treatment of Cancer -CIPN20 ( EORTC -CIPN20) . The 
primary study outcome is CIPN  as measured by the EORTC -CIPN- 20.[54] The EORTC -CIPN20  
includes items that assess CIPN -related symptoms and functional interference in daily activities.  
Multiple studies support the content and construct validity of the EORTC -CIPN20  [55-57] and it w as 
identified as the best available PRO for CIPN a t the NCI CIPN planning meeting. [14] (20-items)  
 
(2) CIPN Symptom I nventory . Individual CIPN symptoms  will be evaluated using weekly averages of 
daily diary 0 – 10 NRS  scores [0 = no symptoms, 10= worst symptom imaginable]  of sensory symptoms 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 19 of 36 
 including hot/burning pain, sharp/ shooting pain, tingling, cramping, and numbness  (Daily Diary). The 
participant will also be asked to rate these symptoms, while thinking about the past week at each visit 
(CIPN S ymptom  Inventory – week recall ). NRS scores and their composites are fre quently used to 
assess symptoms in cancer and pain patients (e.g., MD Anderson Symptom Inventory  [58]). 
Furthermore, the daily diary of a single -item 0 –10 NRS for pain intensity is commonly used as the basis 
for approval of chronic pain medications by the FDA. [59] The symptom diaries  will instruct  the 
participants to focus on the symptoms in their lower limbs and perform ratings in the evening before 
bed while considering the past day. Based on our preliminary data, a composite measure of these 
symptoms in the lower limbs may be particularly responsive to the TENS intervention.  Our pilot data 
also indicate that the outcome that is based o n the average of the weekly symptom ratings has 
considerably less variability than the single day ratings (i.e., standard deviation of 4.6 vs 5.7) and could 
significantly decrease th e sample size requirement of a future trial.  (5 items ) 
 (3) Treatment -Induced Neuropathy Assessment Scale (TNAS).  The TNAS is a PRO that assess es 
symptoms and functional interference from CIPN  in 2 separate domains.  It was developed and refined 
in multiple stages, including interviews with patients and clinicians t o develop content valid items, and 
cognitive debriefing to assess the understandability  of the items. It has acceptable reliability  and 
sensitivity to change .[60, 61] (9 items)  
 
CIPN i nterference. CIPN interference  in general activity, mood, walking, normal work, relationships, sleep, 
and enjoyment of life will be measured using the CIPN Interference Questionnaire , which uses  0 – 10 
NRSs  [0 = does not interfere, 10 = completely interferes]  adapted from the Brief Pain Inventory  (BPI) . [62] 
The BPI  is a well- established measu re used to assess chronic pain in clinical trials and  clinically.  (7 items)  
 Depression  and anxiety . Depression will be measured using the PROMIS -Depression Short Form 8A 
(PROMIS 1 ). Anxiety wi ll be measured using the PROMIS -Anxiety  Short Form 7A  (PROMIS 2 ). PROMIS 
is a set of person -centered measures that evaluates physical, mental, and social health in the general 
population and those living with chronic conditions. The measures were developed with NIH funding using 
state of the art psychometric techniques and include brief measures that aim to maximize precision and brevity . [63] The Depression and Anxiety Short Forms have acceptable reliability and validity in several 
disease contexts . [64-67] In particular, they have demonstrated internal consistency, convergent validity 
with legacy measures, and sensitivity to change in a sample of cancer patients .[68] (15 items)  
 
Physical f unction.  Physical function will be measured using the PROMIS -Physical Function Short Form 
8b (PROMIS 3 ). In a large study of multiple clinical conditions, the PROMIS Physical Function measure 
was sensitive to change from interventions that would be accepted to improve physical function and was 
able to distinguish between groups of patients with different degrees of physical limitation.  [69] In a cohort 
of almost 5000 c ancer patients, multiple PROMIS  Physical Function Short Forms showed high internal 
consistency and good  convergent and discriminant validity .[70] (8 items)  
 
Single- Item Questions  
 
(1) Participant expectation questionnaire. Participant expectation regarding the likelihood of TENS 
helping their CIPN will be assessed using a 1 –  5 likert -type scale. The question will be phrased as 
follows: “ How likely do you think it is that a TENS device can im prove your neuropathy symptoms?” 
[1= Not at all Likely, 3 = Somewhat Likely, 5= Very Likely].  
 
(2) Overall impression of change in neuropathy . Impression of change in neuropathy symptoms will 
be measured using a single question  (i.e., General Impression of Neuropathy form)  that utilizes a  1 
– 7 scale adapted from the patient global impression of change (PGIC). [
71] The PGIC is commonly 
used in chronic pain trials to assess patient’s experience of the change this beginning a treatment or 
clinical trial. [72] 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 20 of 36 
  
(3) Overall impression of change in activity . Impression of change in ability to be active will be 
measured using a single question (i.e., General Impression of Activity  form)  that utilizes a 1 –  7 scale 
adapted from the patient global impression of change. [71]  The PGIC is commonly used in chronic pain 
trials to assess patient’s experience of the change this beginning  a treatment o r clinical trial. [72] 
 (4) Blinding  will be assessed using the Blinding Questionnaire  at the Week 6 visit by asking 
participants and blinded coordinators  to guess which device the participant received and the basis for 
that guess (i.e., for participants, symptom relief vs. feel of the stimulation).  
 
(5) Changes in concomitant medications.  Participants will be asked if they changed any of their pain 
medications (other than acetaminophen or NSAIDs) throughout the study. This information will be captured on the Changes in concomitant analgesic medications  form.  
 
Functional Exam-Based Outcomes  
 
Balance. Balance will be measured using the balance subscale of the Short Physical Performance Battery 
(SPPB). The SPPB has been used in multiple studies of cancer patients. [73-75] The SPPB balance 
subscale is a composite measure of timed feet together, semi -tandem, and tandem foot stands. [76] Results 
will be recorded in the SPPB data collection form  
 
Descending i nhibition.  Descending inhibition will be evaluated using a Conditioned Pain Modulation 
(CPM ) test. The CPM test is a common test used in chronic pain studies in a wide variety of patient types, 
including those with CIPN,  [27] diabetic neuropathy,  [77] osteoarthritis,  [78] fibromyalgia,  [79] irritable 
bowel syndrome,  [80] carpel tunnel syndrome,  [81] and low back pai n. [82] The CPM tests includes 2 
temporary pain stimuli, a  test stimulus  that is administered before and after  a conditioning stimulus . The 
difference in the result of the test stimulus before and after the conditioning stimulus is indicative of the 
efficiency of the participant’s descending inhibitory pathways. The CPM test has  demonstrated ability to 
distinguish between groups as expec ted [83] and intra -session reliability. [84]  In this case the test stimulus 
will be pressure and the conditioning stimulus will be brief  (up to approximately 30 sec -1 minute)  immersion 
in cold water. Specifically, the participant’s pressure pain threshold (PPT) (i.e., the point at which a 
pressure stimulus first becomes painful) is measured on the trapezius muscle  3 times  (i.e., the test 
stimulus). Subsequently the participant is asked to immerse their right hand in ice water (~4° C) for 15 
seconds (i.e., the conditioning stimulus), at which point they will be asked to rate t he pain in their hand and 
then 3 subsequent pressure pain threshold measures will be taken on the trapezius muscle while the hand 
is held in the water . Participants will be told that they may  remove their hand from the cold water before 
the 15 seconds has elapsed if it is too painful for them. If they remove their hand prior to the 15 seconds  
the post conditioning stimulus PPT measurements will be taken  at that time. The temperature of the water 
will be monitored for consist ency and to ensure it does not go below 4 °C. Results will be recorded in the 
CPM data collection form . 
 
Lower -limb sensation threshold.  Lower limb sensation will be evaluated using a monofilament test 
threshold test. In the monofilament test, the participants are asked to close their eyes while each 
monofilament is applied (or not) to the dorsum of the big toe in random order 10 times (i.e., trials). With 
each trial, the participant is asked to state whether they think  the filament touch their skin. For each set of 
10 trials with a single monofilament, if the participant guesses correctly ≥ 9 times the next weaker 
monofilament is used. If the participant guesses correctly 7 or 8 times this filament is documented as the 
participant’s sensation threshold. If the participant guesses correctly ≤ 6 times the next stronger filament 
is trialed. The participant’s sensation threshold is the outcome of the test. Results will be recorded on the 
Scoring Sheet for the Lower Limb Sens ation test and then entered in REDCap in the Lower -limb 
sensation threshold data collection form . 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 21 of 36 
  
Feasibility Outcomes  
 
Proportion of screened participants who enroll  in the study  will be extracted from study records.  
 Outcome measure completion rates  for PROs, balance measures,  CPM tests , lower limb sensation test,  
and Quell Health App usage will be extracted from study  records. The proportion  of total instances that 
each outcome was completed appropriately in the baseline and endpoint visits will be evaluated.  
 
Treatment adherence  will be evaluated using data downloaded from the TENS device a fter the  Week 6 
Visit (i.e., the number of treatment sessions/day and the time that the device was in contact with the skin). 
The following summaries regarding adherence will be explored:  (1) The mean number of study days that 
each participant used the device for at least the amount of time pr escribed based on data downloaded 
from the device, (2) t he proportion of participants who used the device for at least 5 hours per day on at 
least 70% of the days based on data downloaded from the device.  
 
Potential reasons for low treatment adherence will be captured using a  Qualitative Feedback 
Questionnaire.   
 Reasons for ineligibility or refusal to enroll captured on the Screening log  will be evaluated to 
determine if changes in the study design could greatly improve r ecruitment rates of a future study.  
 
5.5 Potential Risks  
 There are four potential risks associated with participation in the study  
 
(1) Physical harm associated with the intervention. There is a small risk of skin irritation at the site 
where the electrodes attach the TENS device to the skin. In addition, 3 of 26 participants in our pilot study  
reported mild worsening of neuropathy symptoms or new, abnormal sensations after starting the TENS 
device. Although it is unknown whether these symptoms were a physiological or psychosomatic 
consequence of the TENS treatment, all symptoms disappeared af ter stopping the TENS treatment  for 2 
participants . One participant felt that the new sensations were acceptable considering the perceived 
benefits of the TENS treatment and  decided to continue using the TENS device.   
  
(2) Physical harm associated with t he assessments.  The conditioned pain modulation test involves 
evoking pain using pressure from an algometer and temporary immersion in cold water . These pains are 
temporary.  
 
(3) Emotional distress.  The assessments explore participants’ feelings regarding their CIPN symptoms 
and associated functioning. Some participants may become distressed when they think about these topics.  
 
(4) Loss of confidentiality.  Participants’ data from assessments and clinical factors extracted from the 
medical record will need t o be stored. A  small chance exists that a confidentiality breech will result in 
participants’ sensitive health information being made available to parties outside the research team.  
However, participants’  name s and contact information will be kept separately from the study data to 
minimize the chance of loss of confidentiality .  If information from this study is published or presented at 
scientific meetings, participants’ names  and other personal information will not be used.  
  
5.6 Emergency  Study D evice  Disclosure  
 
Unblinding of the study device is ONLY permitted in the case of serious and unexpected adverse events 
that are definitely, probably or possibl y associated with the use of the study device AND if knowledge of 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 22 of 36 
 the study treatment arm receiv ed is necessary for interpreting the medical event and related tr eatment of 
that medical event. In such cases, the treating MD or their designee can be given the treatment group 
assignment from the unblinded coordinator . This event needs to be document ed and the IRB notified within 
seven days.  Documentation should be sent to the email address below and include participant ID number, 
site investigator, and reason for unblinding in the message:  
 
Linda Spath  
linda_spath@urmc.rochester.edu  
585-275-1364  
 
Participants that require emergency study device disclosure will discontinue use of the study device. The 
research team may continue to follow the study participant for assessment data with participant and treating provider approval.  
 
5.7 Costs to the Part icipant  
 
 If participants do not have a data plan on their cellular phone or device, they will incur data charges 
associated with using the App and transferring the data to the cloud if they are not connected to a Wi-Fi 
source. If participants do have a data plan, it is very unlikely that they will incur extra charges for data 
usage because the approximate amount of data used by the App if it is opened 5 times per day is 2.5Mb, 
which is a fraction of the minimally available cellular data plan (i.e., 1GB) and home internet service plans 
(i.e., 1000GB).  
 
5.8 Payment for Participation 
 
Participants will not receive payment for the study.  However, all participants will receive, for free, an active 
TENS device after completion of the study that they can keep after the end of the study . 
 
5.9 Contraindications  
 
With the exception of entry  criteria listed in Section 3, t here are no restrictions on who can safely use 
TENS. Participants should not get the TENS device wet and therefore should not, for example, wear it in 
the shower or when swimming. In addition,  the TENS device should not be worn continuously for more 
than 12 hours to minimize potential skin irritation. Finally, the TENS device should not be used while 
driving.  
 5.10 Concomitant Medications 
 
There are no limitations on concomitant medications  taken at stable dosages (see eligibility  criteria in 
Section 3.2) . 
 
5.11 Adherence  
 
Treatment adherence will be monitored during the study using data downloaded from each participant ’s 
Quell Health Account. The Quell Health Account will be set up at the baseline visit using  a de-identified, 
unique Study E mail address created for the study to protect participants’ privacy. These data will be used 
to provide real -time feedbac k to participants and in turn hopefully optimize adherence. Treatment 
adherence will be evaluated as an outcome of the study  using data downloaded after the  Week 6  Visit 
when the coordinator links the App (i.e., the number of treatment sessions/day and the time that the device 
was in contact with t he skin).  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 23 of 36 
 6.  STUDY DEVICE  DISTRIBUTION 
 
6.1 Availability  
 
Activ e and placebo TENS devices  will be supplied by the URCC NCORP Research Base.   
 6.2 Distribution   
 
The active and placebo TENS devices  will be supplied by the URCC Research Base . Each device includes 
a package of 2 electrodes. A second package of 2 electrodes will be sent with each device. Four  electrodes 
should last approximately 8 weeks (2 weeks each). Extra electrodes can be requested from t he Research 
Base if necessary. Devices  will only be released to URCC NCORP Research Base affiliates approved to 
participate.  Upon approval to participate,  1 active and 1 placebo device will be shipped to each site.  Once 
a device is distributed to a participant,  the site Investigator , or their authorized designee should request a 
replacement device be shipped to their site so that each site has 1 active and 1 placebo device in stock at 
all times. If more than 1 participant is enrolled on the study and both participants are completing the 
baseline week at the same time, the site Investigator or designee can request a second pair of devices to 
ensure that the c orrect device will be available for the participant at the Baseline visit. Device s are 
requested by emailing the URCC NCORP Research Base and should include complete shipping and 
contact information and device group (i.e., orange or blue dot sticker ). All TENS devices used by 
participants during the study will be  returned to the URCC NCORP Research Base within 3 months of 
completion of the 6 Week Visit.  
 
Alexandra O’Connell  
URCC_19085@URMC.Rochester.edu
 
585-275-1067  
  
 
6.3  Device Accountability  
 
The NCORP site, and responsible party designated at the site, must maintain a careful record of the 
inventory and disposition of all devices  and packets of electrodes  received from the URCC NCORP 
Research Base  using the Investigational Device Accountability Record. All receipt  and dispensation of 
study devices should be recorded, including date,  participant  ID# and initials,  serial number from the back 
of the device, and blinded device label . All unused devices  will be returned to URCC at the end of the 
study . 
 
6.4 Packaging and Labeling 
 
Neurometrix will provide to the Research Base the devices in identical packaging with a key that will identify 
the active and placebo devices via the serial numbers that Linda Spath  (linda_spath@urmc.rochester.edu)  
will have access to.  URCC Research Base staff will apply the coded labels (i.e., orange or blue dot 
stickers). Neither the Study Chair, Co- chairs, nor statisticians will have access to the label key so they will 
remai n blinded until after the primary and secondary analyses are completed.   
 
6.5 Storage  
 
The devices  will be stored at room temperature. Study devices  will be stored away from heat and moisture.  
Study devices  will be stored in a secured location that is only  accessible by approved study personnel.  
 
7.  CRITERIA FOR EVAL UATION AND ENDPOINT DEFINITION  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 24 of 36 
  
7.1 Primary Endpoint  
 
The primary study endpoint is CIPN as measured by the mean European Organisation for Research and 
Treatment of Cancer -CIPN20  (EORTC -CIPN20 ) [54] score after 6 weeks of device use.   
 
7.2 Off-Device Criteria  
 Participants may  stop using the study device for the following reasons: (1) completed the protocol -
prescribed intervention, (2) adverse event or serious  adverse event,  or (3) if they want to for any reason. 
Participants will continue to be followed, if possible, in order to collect endpoint data acc ording to the 
schedule of study procedures  (see Section 5.3 ).  
 7.3 Off-Study Criteria  
 
The following are among the reasons that participants may leave the study:  (1) the protocol intervention 
and any protocol -required follow -up period is completed, (2) adverse event/serious adverse event, (3) lost 
to follow -up, (4) withdraw al of consent, (5) death, (6) determination of ineligibility (including eligibility error ), 
(7) pregnancy , or (8 ) if they want to for any reason.  
 
8.0 REPORTING ADVERSE EVENTS  
 
The prompt reporting of adverse events is the responsibility of each investigator engaged in clinical 
research, as required by federal regulations. Adverse events must be described and graded using the 
terminology and grading categories defined in the NCI’s common terminology criteria for adverse events  
(CTCAE), version 5.0. The CTCAE is available at  
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
. 
   The relationship to the study intervention  and the severity of each adverse event as judged by the 
investigator must be recorded.  Attribution to protocol treatment for each adverse event must be 
determined by the investigator and reported on the required forms, using the codes provided.  
 
8.1 Definitions  
 
Adverse event (AE)  is any untoward medical occurrence associated w ith the use of a medical product, 
which does not necessarily have a causal relationship with its use.  An adverse event can be any unfavorable and unintended sign (including abnormal laboratory test results), symptom, or disease 
temporally associated with the use of the study product or not considered related to the study product.  
The relationship of each adverse event to the study interventions must be recorded as one of the choices 
on the scale described below.  
 Table 6. Attribution. Categories to define the relationship between t he adverse event and study 
device/intervention.  
 
ATTRIBUTION  DESCRIPTION  
Unrelated  The AE is clearl y NOT related to the study device  /intervention  
Unlikely  The AE is d oubtfully related to study device  /intervention  
Possible  The AE may be related to study device /intervention  
Probable  The AE is likely related to study device /intervention  
Definite  The AE i s clearly related to study device /intervention  
 
8.2 Serious Adverse Event (SAE) .   
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 25 of 36 
 A serious adverse event is defined as any adverse medical event (experience) that results in at least one 
of the outcomes listed below:  
1. Death 
2. Life-threatening 
3. Requires inpatient hospitalization or prolongation of existing hospitalization.  
4. Results in persistent or significant disability/incapac ity with substantial disruption of the ability to 
conduct normal life functions.  
5. Congenital anomaly/birth defect.  
6. A medical event that may not result in death, be life threatening, or require hospitalization may be 
considered an SAE when, based upon medical judgment, it may jeopardize the patient or 
participant and may require medical or surgical intervention to prevent one of the outcomes listed 
in this definition.  
 
Hospitalization (or prolongation of hospitalization) .  For AE reporting purposes, a hospitalization is 
defined as an inpatient hospital stay equal to or greater than 24 hours.  
 
8.3 Reporting  
 
Adverse events will  be assessed by phone in weeks 1, 3, and 5  and at the Week 6 visit .  At each participant 
visit and phone call, the site study staff will assess adverse events by asking participants if they have 
experienced any new symptoms since starting the experimental treatment . They will ask specifically if any 
skin reactions have occu rred. 
 All adverse events, whether observed by study staff or investigator, elicited from or volunteered by the 
participant, should be documented.  Each adverse event will include the date of onset, date of resolution, 
severity, and the relationship to the  study device or study procedures , and any action taken  with respect 
to the study device or intervention.  
 
Recording of the adverse events will occur once the participant signs the cons ent form until the participant  
goes off study.   
 
Adverse events will be reported to the URCC NCORP Research Base using REDCap, which can be 
accessed from the URCC NCORP website.   
Table 7. R eport able adverse events  
Adverse Event  
Attribution  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Unrelated    URCC  URCC  URCC  
Unlikely    URCC  URCC  URCC  
Possible  URCC  URCC  URCC  URCC  URCC  
Probable  URCC  URCC  URCC  URCC  URCC  
Definite  URCC  URCC  URCC  URCC  URCC  
 
Serious adverse events requiring expedited reporting via CTEP -AERS are described below in Section 8.4.  
Serious adverse events not requiring expedited reporting through CTEP -AERS should be entered into 
REDCap and URCC notified within 10 calendar days of learning of the event.  
 
All recorded adverse events reported to the URCC Research Base will be reported to the Data Safety 
Monitoring Committee.  
 
All adverse events that in the opinion of the investigator are clinically significant will be documented and 
followed according to good medical practices.  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 26 of 36 
  
8.4 Responsibilities for Expedited Reporting  
 
URCC NCORP  Research Base affiliates are required to notify the URCC Research Base if a participant 
has an adverse event requiring expedited reporting.  All SAEs that meet expedited reporting criteria defined 
in the reporting table below will be reported via CTEP -AERS, the Adverse Event Expedited Reporting 
System, accessed via the CTEP web site, https://eapps -ctep.nci.nih. gov/ctepaers/pages/task .  
 
Commercial reporting requirements are provided in the table below.  The commercial device used in this 
study is the Quell  TENS Device.  
 
Table 8 . Expedited reporting requirements for adverse events experienced by participan ts 
who have received study device/intervention within 30 days of the last administ ration of 
commercial study device /intervention.   
Attribution  Grade 4  Grade 5(a)  
 Unexpected  Expected  Unexpected  Expected  
Unrelated or Unlikely    CTEP -AERS  CTEP -AERS  
Possible, Probable, Definite  CTEP -AERS   CTEP -AERS  CTEP -AERS  
 
CTEP -AERS .  Indicates an expedited report is to be submitted via CTEP -AERS within 10 calendar days 
of learning of the event (b).  
1. This includes all deaths within 30 days of the last use  of the commercial study device, regardless 
of attribution. Any death that occurs more than 30 days after the last use of commercial study 
device and is attributed (possibly, probably or definitely) to the device/intervention and is not due to cancer recurrence must be reported according to the instructions above.  
2. Submission of the on -line CTEP -AERS report plus any necessary amendments generally 
completes the reporting  requirements.  You may, however, be asked to submit supporting clinical 
data to the Research Base in order to complete the evaluation of the event.   
 
For more  information  see:  
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  
Table 9. Contact Information for NCI Safety Reporting:  
Website for submitting expedited reports  http://eapps -ctep.nci.nih.gov/ctepaers  
AEMD Help Desk (for CTEP)*  301-897-7497 Monday through Friday, 7:00 AM to 7:00 PM (US 
Eastern Time)  
Fax for expedited report supporting Medical 
Documentation for CTEP Trials  301-230-0159  
(Back -up FAX: 301 -897-7404)  
AEMD Help Email:  aemd@tech -res.com  
Technical ( e.g., IT or comput er issues 
ONLY) Help Phone *  1-888-283-7457 or 301 -840-8202  
CTEP -AERS Technical Help Email  ncictephelp@ctep.nci.nih.gov  
CTCAE v 5 Help/Questions Email  ncicctcaehelp@mail.nih.gov  
CTEP -AERS FAQs link  https://eapps -ctep.nci.nih.gov.ctepaers/help/webhelp/CTEP -
AERS%20FAQ.htm  
CTEP -AERS Computer based training link  https://ctep.cancer.gov/protocolDevelopment/  
electronic_applications/adverse_events.htm  
 
Office phone and fax are accessible 24 hours per day 7 days a week (The AEMD phone line is staffed 
from Monday through Friday, 7:00 AM to 7:00 PM ET. Any phone call after these hours  will go to voicemail. 
Please leave contact information and the phone call will be returned the following business day.  
 Follow -up of SAE .  Site staff will send follow -up reports as requested when addi tional information is 
available. SAEs will be  followed until resolved, especially for those related to the commercial study device.  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 27 of 36 
  
9. STUDY MONITORING  
 
9.1 Data Management Summary   
 This project will collect data in multiple formats: paper documents and electronic questionnaires (REDCap).  
 When written, hard -copy (paper) data are received at the URCC NCORP Research Base, they are 
processed as follows:  
1. Data are visually checked line by line for missing, duplicate, ambiguous or unreasonable responses and if found, the originating site is queried for such data.  
2. In response to a query, the form is amended per good clinical practice ( GCP ) the change is 
documented  and the form is re -submit ted to the research base.  
3. All paper forms are scanned via Teleforms software into tables in an Access database. Again, any 
missing, duplicate or ambiguous data found at this step generates a query to the originating site.  
4. The electronic database tables are visually checked, line by line, against the corresponding forms 
for accuracy.  
5. Queries are also generated if data are not received within 14 days of the assessment . 
6. When all data have been received on any given case, a chart audit is performed to ensure receipt and accuracy of all required data.  
7. All paper documents are stored in locked file cabinets or in locked, limited access file rooms. The 
electronic Access databases of those scanned documents are on password protected drives 
located behind University of Rochester firewalls, with limited access.  
 Data entered into REDCap are reviewed for accuracy and stored in the University of Rochester secure 
REDCap  database. Queries are generated for any questionable or late data.  
On-site audits are conducted at leas t every three years  in accordance with NIH/NCI Clinical Trials 
Monitoring Branch ( CTMB ) guidelines .  The primary objective of an on -site audit is to document compliance 
of the NCORP site with protocol and regulatory requirements, verify accuracy of data by  comparing 
submitted data to source documents at the NCORP site, and to provide information on good clinical 
practices in study conduct and data management. The equivalent of 10% of cases accrued at the site will 
be audited.  All auditing is done as per NIH /NCI CTMB Guidelines.  
 
 
9.2 Schedule of Data Collection   
 
Table 10. Forms to Be Kept  
FORMS  Screening  Baseline  Week 6  
Participant Forms (paper)  
On-Study   X  
Expectation Questionnaire   X  
EORTC CIPN20   X X 
Daily Diary (CIPN symptoms / rescue medication usage) *  X X 
CIPN S ymptom  Inventory – week recall  X X X 
TNAS   X X 
PROMIS 1  X X 
PROMIS  2  X X 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 28 of 36 
 PROMIS 3  X X 
CIPN Interference Questionnaire   X X 
General Impression of Neuropathy    X 
General Impression of Activity    X 
Blinding Question naire    X 
Qualitative Feedback Questionnaire    X 
Coordinator Forms (REDCap1, paper2 ) 
Eligibility c hecklist  (Medical Record , Clinician -reported,  
and Patient -reported items)1 X   
Consent f orm2 X   
Clinical record i nformation  form1 X   
TENS Device Settings form1  X  
CPM data collection form1 X X X 
SPPB Balance form1  X X 
Lower -limb sensation threshold data collection form1 X X X 
Coordinator blinding question1   X 
Changes in concomitant analgesic medications form1   X 
Adverse Event (AE) Form1**   X 
 Screening  log completed for patients who are approached, but not consented  
Submit chemotherapy  treatment notes from participant’s medical record at Screening 
 
Telephone Contact Sheet to be  completed with each phone call   
* Daily diary will be completed during the week between the Screening and  Baseline visit s (collected at 
the B aseline Visit) and during Weeks 4 (i.e., day 21 –  28) and 6 (i.e., day 35 –  42) (collected at 6 Week 
visit).  
** Adverse Events are also assessed  during Week 1, 3, 5 phone calls  
 
9.3 Data and Safety Monitoring Plan  
 
Data Safety Monitoring Committee.  The Director of the URCC delegates responsibility for continued 
review and monitoring of all clinical trials conducted by the URCC to the James P Wilmot Cancer Center 
(JPWCC)  DSMC. This committee provides oversight of study progress and safety by review of accrual and 
adverse events at annual  (or biannual)  meetings. Any adverse event requiring expedited review per 
protocol  will be submitted to the JPWCC  DSMC for determination as to whether further action is required. 
Interim meetings are scheduled, as needed, to address specific issues that require immediate attention to 
assure participant  safety. The DSMC:  
1. Reviews assigne d clinical trials conducted at the URCC for progress and safety  
2. Reviews all adverse events requiring expedited reporting as defined in the protocol  
3. Reviews reports generated by the URCC data quality control review process  
4. Submits recommendations for corrective actions to the Protocol Review Committee and the 
Principal Investigator  
 The DSMC  will review study progress and cumulative reports of adverse events either bi -annually or 
annually (determined by the DSMC). Once the final protocol is submitted t o NCI, the protocol will be 
submitted to the Peer Review Committee for review and frequency of review determined.  An overall 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 29 of 36 
 assessment of accrual and adverse events will enable the committee members to assess whether 
significant benefits or risks are occurring tha t would warrant study closure. Interim meetings are scheduled, 
as needed, to address specific issues that require immediate attention to assure participant safety  
 The URCC will notify the NCORP sites immediately of any serious safety concerns  identified by the DSMC.  
DSMC reports will be available for download on the research base website.  
 
In general, outcome data are  not made available to individuals outside of the JPWCC  DSMC until accrual 
has been completed and all participants  have complet ed their treatment.  At this time, the JPWCC  DSMC 
may approve the release of outcome data on a confidential basis to the trial Principal Investigator for planning the preparation of manuscripts and/or to a small number of other investigators for purposes o f 
planning future t rials. Any release of outcome data prior to the JPWCC  DSMC’s recommendation for 
general dissemination of results must be reviewed and approved by the JPWCC DSMC.  
 
Safety Coordinator.   All adverse events reported to URCC are entered into a REDCap database and can 
be monitored through automated reports. The Safety Coordinator monitors adverse event rates utilizing 
this database. If the study has had two or more of the same SAEs reported in a month or more than six of 
the same SAEs in six m onths, the DSMC will review the summary of SAEs, discuss events with the Study 
Chair, and conduct a more detailed review with the Study Chair. The Data Safety Monitoring Chair will 
determine if further action is required.  The Safety Coordinator:  
1. Forwards  all adverse events requiring expedited reporting to the URCC Data Safety Monitoring 
Committee Chair who determines if immediate action is required  
2. Maintains a database of all adverse events requiring expedited reporting  
3. Ensures all reports are available for all meetings of the DSMC  
4. Monitors adverse event rates utilizing the study  database.  
 
9.4 Record Retention  
 Clinical records for  all participants, including REDCap forms,  all source documentation (containing 
evidence to study eligibility, history and physical findings, laboratory data, results of consultations, etc.), 
as well as IRB records and other regulatory documentation will be retained by the Investigator in a secure 
storage facility in compliance with Health Insurance Portability and Accountability Act (HIPAA), Office of 
Human Research Protections (OHRP), Food and Drug Administration (FDA) regulations and guidelines , 
and NCI/DCP requirements, unless the standard at the site is more stringent.  Records  will be retained for 
at least five years after the date of completion of the research. The records should be ac cessible for 
inspection and copying by authorized persons of the Food and Drug Administration.  
 10. STATISTICAL CONSID ERATIONS  
 10.1  Quality Control.  Established standardized data quality procedures are used for all URCC NCORP 
Research Base studies. Data will be entered on scannable (Teleforms) or electronic forms in REDCap and 
electronically transferred to Microsoft Office databases. Data will be inspected visually. Data distributions 
will be evaluated to identify any outliers that will  be inspected for possible mistakes. If no mistake is found 
for an outlier, it will remain in the data. Statistical analyses will be performed using SAS, JMP, or R  as 
appropriate .  
 
10.2  Analysis set and Missing Data.  All participants  who are randomized will be included in the 
analyses. All efforts will be made to prevent missing data. We will use multiple imputation methods that 
assume missing at random for the primary and secondary analyses. A sensitivity analysis using pattern 
mixture methodology that assumes missing not at random will be used to evaluate the impact of 
missingness on the results.
85  
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 30 of 36 
 10.3  Sample Size Estimation.  Since this is a phase II preliminary eff icacy trial, the primary analysis will 
be performed at the two- tailed 20% significance level (i.e., alpha=0.2).86 A sample size of 126 evaluable 
participants will provide 80% power to detect a 0.4 effect size (standardized mean difference)  in the primary 
analysis. Assuming 15% withdrawal, we will randomize 150 participants.  
 
10.4  Primary Analysis.  The effects of TENS on CIPN will be estimated using analysis of covariance 
(ANCOVA). The model will include CIPN20 at Week 6 as the outcome, tre atment group as the factor, and 
study site and the baseline CIPN20 score as covariates . Additionally, to explore potential large impacts of 
cancer type, chemotherapy class ( i.e., platinum, taxane, other), and analgesic consumption (≥30% vs. 
<30% decrease i n number of days  acetaminophen and/or NSAIDs  were taken ), we will add these factors 
to the above model  for sensitivity analyses . We will also perform subgroup analyses separately based on 
these factors to identify possible differential intervention effects  to inform the design of a future study. 
Distributional assumptions (e.g. normality of residuals) will be evaluated and, if necessary, appropriate 
transformations or nonparametric methods will be used.   
 
10.5  Secondary Analyses.  ANCOVA analyses as in the primary analysis will be used for individual 
symptoms (i.e., hot/burning and sharp/ shooting pain,  numbness, tingling, and cramping (0 – 10 NRS)). For 
each of the symptoms, baseli ne and Week 6 scores will be calculated as the mean of weekly daily diary 
scores during the week between Screening and Baseline and Week 6, respectively.  
 
10.6  Exploratory Analyses.  
(1) ANCOVA analysis as in the primary will be used to investigate the effects of TE NS on exploratory 
outcomes (i.e., balance (SPPB  balance subscale), descending inhibition (CPM test), physical function 
(PROMIS short form ), CIPN -interference in daily life, CIPN measured by TNAS and CIPN symptom 
inventory composite measure, depression and anxiety (PROMIS short forms) ) at baseline and at Week 6 
visits.  
 
(2) Analysis of variance (ANOVA) or an appropriate non- parametri c method ( e.g., Wilcoxon test) if the  
normal ity assumption is not satisfied will be used to evaluate the between arm differences in participant -
perceived changes in CIPN symptoms and participant -perceived change in ability to be active.  
 
(3) Descriptive statistics will be used to characterize the distribution of descending inhibition as measured 
by CPM at baseline. Additionally, the correlation of descending inhibition with CIPN severity (via CIPN20, 
TNAS,  and symptom NRS scores) will be evaluated using a Spearman’s correlations.  
 
(4) To explore the predictive effects of baseline descending inhibition on response to TENS, ANCOVA 
analysis will be used to investigate whether baseline descending inhibition  predicts the effect of TENS on 
CIPN.  The model will include CIPN20 at Week 6 as the outcome, baseline CPM test result, treatmen t 
group, and baseline CPM test result x treatment group interaction as factors, and study site and the 
baseline CIPN20 score as covariates . 
 
(5) To explore mechanistic associations between changes in descending inhibition and CIPN symptoms, 
we will use mediation analysis technique (the method initially formalized by Baron and Kenny,87 extended 
to clinical trial settings by Kraemer,88 and methodologically updated by MacKinnon et al.89, 90). Specifically, 
we will use path modeling to estimate indirect (mediation) effects of changes in the CPM test on CIPN 
sympt oms, and bootstrapping to estimate the 95% confidence intervals. The MPlus software will be 
utilized.  
 
(6) The proportion of participants  who decreased “as -needed” usage of acetaminophen  and NSAIDs 
(defined as taking  acetaminophen or NSAIDs , on a verage, at  least 30% fewer days  per week in the last 
week  of the trial compared to the baseline week) will be compared by groups using a Chi- Square  test. 
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 31 of 36 
 (7) The proportion of participants  who report, for the impression of change in CIPN symptoms question 
“very much improved”, “much improved”,  “minimally improved”,  “no change”, “minimally worse”, “much 
worse”,  and “very much worse”) will be compared between treatment groups using a Cochran Armitage 
Trend Test . 
 
(8) The proportion of participants whose sensa tion threshold from the monofilament test improved will be 
reported together with the 95% confidence interval  (CI) and tested against the null hypothesis of no 
improvement.  
 
(9) Descriptive statistics and 95% CIs will be used to assess  the percentage of participants and outcome 
assessors that correctly identify the group to which the participant was assigned as well as the basis for 
the guesses.  
 (10)Test, re-test reliability for the CPM test will be evaluated using Intraclass correlati on coefficients (ICCs). 
Test, re-test reliability for the lower limb sensation threshold test will be measured using Kappa statistics.  
 
10.7  Sensitivity analyses.  
 
(1) Primary and secondary analyses will be repeated in the subset of participants who adher e to the 
treatment (i.e., adhere to the treatment on > 70% of the study days).  
 
10.8  Feasibility analyses.  
 
(1) Descriptive statistics will be used to summarize the following quantitative feasibility outcomes:  
(a) The proportion and 95% CI  of screened (i.e., approached)  patients who enroll in the study.  
(b) The proportion and 95% CI  of randomized participants who adhere to the treatment and complete 
the primary assessment.  
(c) The proportion and 95% CI  of randomized participants who complete the CPM  test. 
(d) The proportion and 95% CI  of randomized participants who use the device for at least 5 hours / 
day on at least 70% of the study days.  
 
(2) The participant -reported reasons for low adherence will be summarized by identifying common themes 
in the qualitative feedback questionnaire.  
 10.9  Evaluation of Toxicity /Adverse Events  
 
Descriptive statistics will be used to summarize AEs in active and placebo device groups. SAEs will be 
summarized separately as will AEs concluded to be likely related to the treatment.  
 
10.10  Interim Analysis 
 
No interim analyses are planned due to  the fact that TENS is considered nonsignificant risk by the FDA 
per the 2006 FDA’s “Significant Risk and Nonsignificant Risk Medical Devices” Guidance. [51]    
 
10.11  Ancillary Studies 
 
Not applicable 
 
11. ETHICAL AND REGULA TORY CONSIDERATIONS  
 
11.1 Form FDA 1572 
 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 32 of 36 
 Not applicable.  
 
11.2 Other Required Documents (IND studies only)  
 
Not applicable.  
 11.3 Institutional Review Board Approval  
 Prior to initiating the study and receiving study devices , the Investigators at the NCORP  will obtain written 
approval to conduct the study from the NCI Central IRB. Should changes to the study become necessary, 
protocol amendments will be submitted to the Division of Cancer Prevention ( DCP ) PIO according to DCP  
Amendment Guidelines. The DCP -approved amended protocol must be approved by the CIRB prior to 
implementation of any changes . 
 
11.4 Regulatory Approval Process of the Informed Consent Document  
 
Prior to study initiation, the informed consent document will be reviewed and approved by National Cancer 
Institute (NCI) Division of Cancer Prevention (DCP), and the Central IRB (CIRB).  Any subsequent changes 
to the informed consent must be approved by NCI DCP and CIRB prior to initiation.  
 11.5 Submission of Regula tory Documents  
 
All regulatory documents should be forwarded to the URCC as follows:  
 
URCC_Regulatory@urmc.rochester.edu  
 
11.6 Other  
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable regulatory requirements.  
 
12. REFERENCES  
 
1. Seretny, M., et al., Incidence, prevalence, and predictors of chemotherapy -induced peripheral 
neuropathy: A systematic review and meta -analysis.  Pain, 2014. 155(12): p. 2461 -2470.  
2. NCI. Sureillance, Epi demiology, and End Results Program . Available from: 
https://seer.cancer.gov/statfacts/ . 
3. Kneis, S., et al., Balance impairments and neuromuscular changes in breast cancer patients with 
chemotherapy -induced peripheral neuropathy.  Clin Neurophysiol, 2016. 127 (2): p. 1481 -90. 
4. Monfort, S.M., et al., Gait, balance, and patient -reported outcomes during taxane -based 
chemotherapy in early -stage breast cancer patients.  Breast Cancer Res Treat, 2017. 164(1): p. 69 -
77. 
5. Gewandter, J.S., et al., Falls and functi onal impairments in cancer survivors with chemotherapy -
induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.  Support Care 
Cancer, 2013. 21(7): p. 2059- 66. 
6. Kolb, N.A., et al., The Association of Chemotherapy -Induced Peripheral Neuropathy Symptoms 
and the Risk of Falling.  JAMA Neurol, 2016. 73 (7): p. 860 -6. 
7. Bao, T., et al., Long -term chemotherapy -induced peripheral neuropathy among breast cancer 
survivors: prevalence, risk factors, and fall risk.  Breast Cancer Res Treat, 2016. 159 (2): p. 327 -33. 
8. Winters -Stone, K.M., et al., Falls, Functioning, and Disability Among Women With Persistent 
Symptoms of Chemotherapy -Induced Peripheral Neuropathy.  J Clin Oncol, 2017. 35(23): p. 2604-
2612.  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 33 of 36 
 9. Tofthagen, C., Patient perceptions associated  with chemotherapy -induced peripheral neuropathy.  
Clin J Oncol Nurs, 2010. 14(3): p. E22- 8. 
10. Tofthagen, C.S., S.C. McMillan, and K.E. Kip, Development and psychometric evaluation of the 
chemotherapy -induced peripheral neuropathy assessment tool.  Cancer Nurs, 2011. 34(4): p. E10 -
20. 
11. Mols, F., et al., Chemotherapy -induced peripheral neuropathy and its association with quality of 
life: a systematic review.  Support Care Cancer, 2014. 22 (8): p. 2261 -9. 
12. Smith, E.M., et al., Effect of duloxetine on pain, function, and quality of life among patients with 
chemotherapy -induced painful peripheral neuropathy: a randomized clinical trial.  JAMA, 2013. 
309(13): p. 1359 -67. 
13. Gewandter, J.S., et al., Chemotherapy -induced peripheral neuropathy clinical trials: R eview and 
recommendations.  Neurology, 2017.  
14.  National Cancer Institute Symptom Management and Health- related Quality of Life Steering 
Committee Clinical Trial Planning Meeting -   Chemotherapy Induced Peripheral Neuropathy: 
Developing Novel Trials Infor med by Translational Science. Executive Summary . 2017.  
15. Symptom Management & Quality of Life Steering Committee. 2015 Strategic Priorities . 2015.  
16. Ossipov, M.H., G.O. Dussor, and F. Porreca, Central modulation of pain.  Journal of Clinical 
Investigation, 2010. 120 (11): p. 3779- 3787.  
17. Kwon, M., et al., The role of descending inhibitory pathways on chronic pain modulation and clinical 
implications.  Pain Pract, 2014. 14(7): p. 656 -67. 
18. Staud, R., Abnormal endogenous pain modulation is a shared characteristic of many chronic pain 
conditions.  Expert Rev Neurother, 2012. 12(5): p. 577- 85. 
19. Yarnitsky, D., Conditioned pain modulation (the diffuse noxious inhibitory control -like effect): its 
relevance for acute and chroni c pain states.  Curr Opin Anaesthesiol, 2010. 23 (5): p. 611 -5. 
20. Cata, J.P., et al., Altered discharges of spinal wide dynamic range neurons and down -regulation of 
glutamate transporter expression in rats with paclitaxel -induced hyperalgesia.  Neuroscience, 2006. 
138(1): p. 329 -38. 
21. Cata, J.P., H.R. Weng, and P.M. Dougherty, Behavioral and electrophysiological studies in rats 
with cisplatin -induced chemoneuropathy.  Brain Res, 2008. 1230 : p. 91 -8. 
22. Weng, H.R., J.V. Cordella, and P.M. Dougherty, Changes  in sensory processing in the spinal dorsal 
horn accompany vincristine- induced hyperalgesia and allodynia.  Pain, 2003. 103 (1-2): p. 131- 8. 
23. Robinson, C.R., H. Zhang, and P.M. Dougherty, Altered discharges of spinal neurons parallel the 
behavioral phenot ype shown by rats with bortezomib related chemotherapy induced peripheral 
neuropathy.  Brain Res, 2014. 1574 : p. 6 -13. 
24. Robinson, C.R. and P.M. Dougherty, Spinal astrocyte gap junction and glutamate transporter 
expression contributes to a rat model of bo rtezomib- induced peripheral neuropathy.  Neuroscience, 
2015. 285: p. 1 -10. 
25. Weng, H.R., et al., Spinal glial glutamate transporters downregulate in rats with taxol -induced 
hyperalgesia.  Neurosci Lett, 2005. 386 (1): p. 18 -22. 
26. Yang, Y., et al., Spinal changes of a newly isolated neuropeptide endomorphin- 2 concomitant with 
vincristine -induced allodynia.  PLoS One, 2014. 9(2): p. e89583.  
27. Nahman -Averbuch, H., et al., Pronociceptive pain modulation in patients with painful chemotherapy -
induced polyneurop athy.  J Pain Symptom Manage, 2011. 42(2): p. 229- 38. 
28. Sluka, K. and D. Walsh, Transcutaneous Electrical Nerve Stimulation and Interferential Therapy , 
in Mechanisms and management of pain for the physical therapist K. Sluka, Editor. 2016.  
29. Dailey, D.L ., et al., Transcutaneous electrical nerve stimulation reduces pain, fatigue and 
hyperalgesia while restoring central inhibition in primary fibromyalgia.  Pain, 2013. 154(11): p. 2554 -
62. 
30. DeSantana, J.M., L.F. da Silva, and K.A. Sluka, Cholecystokinin receptors mediate tolerance to the 
analgesic effect of TENS in arthritic rats.  Pain, 2010. 148 (1): p. 84 -93. 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 34 of 36 
 31. Kalra, A., M.O. Urban, and K.A. Sluka, Blockade of opioid receptors in rostral ventral medulla 
prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS).  J 
Pharmacol Exp Ther, 2001. 298 (1): p. 257 -63. 
32. Sluka, K.A., C.G. Vance, and T.L. Lisi, High -frequency, but not low -frequency, transcutaneous 
electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn.  
J Neurochem, 2005. 95 (6): p. 1794- 801. 
33. Ma, Y.T. and K.A. Sluka, Reduction in inflammation- induced sensitization of dorsal horn neurons 
by transcutaneous electrical nerve stimulation in anesthetized rats.  Exp Brain Res, 2001. 137(1): 
p. 94 -102. 
34. Sluka, K.A., et al., Spinal blockade of opioid receptors prevents the analgesia produced by TENS 
in arthritic rats.  J Pharmacol Exp Ther, 1999. 289(2): p. 840- 6. 
35. Leonard, G., P. Goffaux, and S. Marchand, Deciphering the role  of endogenous opioids in high-
frequency TENS using low and high doses of naloxone.  Pain, 2010. 151(1): p. 215 -9. 
36. Kumar, D., et al., Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline 
for symptomatic relief.  Diabetes Care, 1998. 21(8): p. 1322 -5. 
37. Kumar, D. and H.J. Marshall, Diabetic peripheral neuropathy: amelioration of pain with 
transcutaneous electrostimulation.  Diabetes Care, 1997. 20(11): p. 1702- 5. 
38. Barbarisi, M., et al., Pregabalin and transcutaneous electri cal nerve stimulation for postherpetic 
neuralgia treatment.  Clin J Pain, 2010. 26(7): p. 567 -72. 
39. Carbonario, F., et al., Effectiveness of high- frequency transcutaneous electrical nerve stimulation 
at tender points as adjuvant therapy for patients with fibromyalgia.  Eur J Phys Rehabil Med, 2013. 
49(2): p. 197 -204. 
40. Cheing, G.L. and M.L. Luk, Transcutaneous electrical nerve stimulation for neuropathic pain.  J 
Hand Surg Br, 2005. 30(1): p. 50- 5. 
41. Lauretti, G.R., et al., The New Portable Transcutaneous Electrical Nerve Stimulation Device Was 
Efficacious in the Control of Primary Dysmenorrhea Cramp Pain.  Neuromodulation, 2015. 18(6): p. 
522-6; discussion 522 -7. 
42. Osiri, M., et al., Transcutaneous electrical nerve stimulation for knee osteoarthritis.  Cochrane 
Database Syst Rev, 2000(4): p. CD002823.  
43. Proctor, M.L., et al., Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea.  Cochrane Database Syst Rev, 2002(1): p. CD002123.  
44. Buchmuller, A., et al., Value of TENS  for relief of chronic low back pain with or without radicular 
pain.  Eur J Pain, 2012. 16 (5): p. 656 -65. 
45. Tinazzi, M., et al., TENS for the treatment of writer's cramp dystonia: a randomized, placebo-
controlled study.  Neurology, 2005. 64 (11): p. 1946- 8. 
46. Yarnitsky, D., et al., Nonpainful remote electrical stimulation alleviates episodic migraine pain.  
Neurology, 2017. 88 (13): p. 1250- 1255.  
47. Wong, R., P. Major, and S. Sagar, Phase 2 Study of Acupuncture- Like Transcutaneous Nerve 
Stimulation for Chem otherapy -Induced Peripheral Neuropathy.  Integr Cancer Ther, 2016. 15(2): p. 
153-64. 
48. Pachman, D.R., et al., Pilot evaluation of Scrambler therapy for the treatment of chemotherapy -
induced peripheral neuropathy.  Support Care Cancer, 2015. 23(4): p. 943- 51. 
49. Gewandter, J., et al., Wireless transcutaneous electrical nerve stimulation device for 
chemotherapy -induced peripheral neuropathy: An open- label feasibility study.  Supportive Care in 
Cancer, 2018. Epub Ahead of Print . 
50. Gewandter, J.S., et al., A phase III randomized, placebo- controlled study of topical amitriptyline 
and ketamine for chemotherapy -induced peripheral neuropathy (CIPN): a University of Rochester 
CCOP study of 462 cancer survivors.  Support Care Cancer, 2014. 22 (7): p. 1807- 14. 
51. US. Information sheet guidance for IRBs, Clinical Investigators, and Sponsors. Significant and 
nonsignificant risk medical devices . 2006; Available from: 
https://www.fda.gov/media/75459/download
. 
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 35 of 36 
 52. Ahmed, S., et al., The Effect of Electric Stimulation Techniques on Pain and Tenderness at the 
Myofascial Trigger Point: A Systematic Review.  Pain Med, 2019.  
53. Rakel, B., et al., A new transient sham TENS device allows for investigator blinding while del ivering 
a true placebo treatment.  J Pain, 2010. 11(3): p. 230 -8. 
54. Postma, T.J., et al., The development of an EORTC quality of life questionnaire to assess 
chemotherapy -induced peripheral neuropathy: the QLQ -CIPN20.  Eur J Cancer, 2005. 41 (8): p. 
1135- 9. 
55. Lavoie Smith, E.M., et al., Assessing patient -reported peripheral neuropathy: the reliability and 
validity of the European Organization for Research and Treatment of Cancer QLQ -CIPN20 
Questionnaire.  Qual Life Res, 2013. 22 (10): p. 2787- 99. 
56. Kieffer , J.M., et al., Evaluation of the psychometric properties of the EORTC chemotherapy -induced 
peripheral neuropathy questionnaire (QLQ -CIPN20).  Qual Life Res, 2017.  
57. Cavaletti, G., et al., Multi -center assessment of the Total Neuropathy Score for chemothe rapy-
induced peripheral neurotoxicity.  J Peripher Nerv Syst, 2006. 11(2): p. 135 -41. 
58. CS, C. The M.D. Anderson Symptom Inventory: User Guide Version 1. 2009; Available from: 
https://www.mdanderson.org/content/dam/mdanderson/documents/Departments -and-
Divisions/Symptom -Research/MDASI_userguide.pdf . 
59. U.S. Food and Drug Administration, C.f.D.E.R., Clinical Outcome Asse ssment Compendium (pilot).  
60.  Mendoza, T.R., et al., Measuring Therapy -Induced Peripheral Neuropathy: Preliminary Development and 
Validation of the Treatment -Induced Neuropathy Assessment Scale. J Pain, 2015. 16(10): p. 1032- 43. 
61. Williams, L.A., et al ., Concept domain validation and item generation for the Treatment -Induced 
Neuropathy Assessment Scale (TNAS).  Support Care Cancer, 2019. 27(3): p. 1021- 1028.  
62. Cleeland, C., Brief Pain Inventory . 1991.  
63. Garcia, S.F., et al., Standardizing patient -reported outcomes assessment in cancer clinical trials: a 
patient -reported outcomes measurement information system initiative.  J Clin Oncol, 2007. 25(32): 
p. 5106 -12. 
64. Schalet, B.D., et al., Establishing a common metric for self -reported anxiety: linking t he MASQ, 
PANAS, and GAD -7 to PROMIS Anxiety.  J Anxiety Disord, 2014. 28(1): p. 88 -96. 
65. Choi, S.W., et al., Establishing a common metric for depressive symptoms: linking the BDI -II, CES -
D, and PHQ -9 to PROMIS depression.  Psychol Assess, 2014. 26(2): p. 5 13-27. 
66. Pilkonis, P.A., et al., Validation of the depression item bank from the Patient -Reported Outcomes 
Measurement Information System (PROMIS) in a three- month observational study.  J Psychiatr 
Res, 2014. 56 : p. 112 -9. 
67. Amtmann, D., et al., Comparing CESD -10, PHQ -9, and PROMIS depression instruments in 
individuals with multiple sclerosis.  Rehabil Psychol, 2014. 59(2): p. 220- 229. 
68. Wilford, J., et al., Validation of PROMIS emotional distress short form scales for cervical cancer.  
Gynecol Oncol, 2018. 151 (1): p. 111 -116. 
69. Schalet, B.D., et al., Validity of PROMIS physical function measured in diverse clinical samples.  J 
Clin Epidemiol, 2016. 73 : p. 112- 8. 
70. Jensen, R.E., et al., Validation of the PROMIS physical function measures in a di verse US 
population- based cohort of cancer patients.  Qual Life Res, 2015. 24(10): p. 2333 -44. 
71. W, G., ed. ECDEU Assessment Manual for Psychopharmacology . 1976, U.S. Department of 
Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and MEntal Health 
Administration: Rockville, MD.  
72. Dworkin, R.H., et al., Core outcome measures for chronic pain clinical trials: IMMPACT 
recommendations.  Pain, 2005. 113(1-2): p. 9 -19. 
73. Gewandter, J.S., et al., Associations between a patient -reported  outcome (PRO) measure of 
sarcopenia and falls, functional status, and physical performance in older patients with cancer.  J 
Geriatr Oncol, 2015. 6(6): p. 433 -41. 
74. Loh, K.P., et al., Associations of sleep disturbance with physical function and cognition  in older 
adults with cancer.  Support Care Cancer, 2017.  
 
 
URCC19085(Amd3) Protocol 06-25-2021.docx 25/2021  Page 36 of 36 
 75. Lee, C.E., et al., A Preliminary Study on the Efficacy of a Community -Based Physical Activity 
Intervention on Physical Function- Related Risk Factors for Falls Among Breast Cancer Survivors.  
Am J Phys Med Rehabil, 2016. 95(8): p. 561- 70. 
76. Guralnik, J.M., et al., A short physical performance battery assessing lower extremity function: 
association with self -reported disability and prediction of mortality and nursing home admission.  J 
Gerontol, 199 4. 49(2): p. M85 -94. 
77. Yarnitsky, D., et al., Conditioned pain modulation predicts duloxetine efficacy in painful diabetic 
neuropathy.  Pain, 2012. 153(6): p. 1193 -8. 
78. Arendt -Nielsen, L., et al., Sensitization in patients with painful knee osteoarthrit is. Pain, 2010. 
149(3): p. 573 -81. 
79. Kosek, E. and P. Hansson, Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects.  
Pain, 1997. 70(1): p. 41 -51. 
80. Piche, M., et al., Widespread hypersensitivity is related to altered pain inhibition processes in 
irritable bowel syndrome.  Pain, 2010. 148 (1): p. 49 -58. 
81. Soon, B., et al., Facilitatory and inhibitory pain mechanisms are altered in patients wit h carpal tunnel 
syndrome.  PLoS One, 2017. 12(8): p. e0183252.  
82. Mlekusch, S., et al., Conditioned Pain Modulation in Patients With Acute and Chronic Low Back Pain.  Clin J Pain, 2016. 32(2): p. 116 -21. 
83. Lindstedt, F., et al., Conditioned pain modulation is associated with common polymorphisms in the 
serotonin transporter gene.  PLoS One, 2011. 6(3): p. e18252.  
84. Lewis, G.N., et al., Reliability of the conditioned pain modulation paradigm to assess endogenous 
inhibitory pain pathways.  Pain Res Manag, 2012. 17(2): p. 98 -102. 
 